Society of ToxicologyMcKeeman, Kim Boekelheide, Hanan N. Ghantous, Angela J. Harris, Michael P. Holsapple, B. Paige Lawrence, Jean F. Regal, Lynette K. Rogers, Sharmilee P. Sawant,

1821 MICHAEL FARADAY DRIVE, SUITE 300, RESTON, VIRGINIA 20190Telephone: 703.438.3115 Fax: 703.438.3113 Email: [email protected]: www.toxicology.org

December 31, 2015

Dear Voting Member of the Society of Toxicology:

The Nominating Committee, including Chairperson Lois D. Lehman-McKeeman, Kim Boekelheide, Hanan N. Ghantous, Angela J. Harris, Michael P. Holsapple, B. Paige Lawrence, Jean F. Regal, Lynette K. Rogers, Sharmilee P. Sawant, and Council Contact Norbert E. Kaminski is proud to present the 2016–2017 nominees for SOT officers and members of SOT-elected committees.

Please mark the ballot in the appropriate spaces and be sure to include your signature and printed full name. Blank spaces are provided for write-in candidates. Fax the ballot, with the accompanying cover sheet that also includes your signature, printed full name, and address, to the offices of Dixon Hughes Goodman, LLP (Certified Public Accountants); Fax: 240.403.3701, Attn: Debbie Orozco, Ballot Clerk.

Your ballot will be valid only if you have printed and signed your name on both the fax cover sheet and the ballot sheet. All valid ballots received by February 1, 2016, will be counted.

Alternatively, you may choose to vote using the online ballot processes, available on the SOT website at http://www.toxicology.org/application/ms/2016ballot.aspx. Just log in using your email and SOT password to gain access to the ballot. After you review the candidate biographical information, make your selections by marking the appropriate spaces next to the candidates’ names, or complete text fields for write-in candidates. Thank you for participating in this important election process. Follow the results in the Special Issue of the Communiqué in late February. I hope that your 2015 was most successful and satisfying and that I have the pleasure of seeing you in March at our Annual Meeting in New Orleans, Louisiana.

Sincerely,

Peter L. GoeringPresident

Enclosures

2015–2016 COUNCILPRESIDENT

Peter L. Goering, PhD, DABT, ATS

Silver Spring, MD

VICE PRESIDENTJohn B. Morris,

PhD, ATS Storrs, CT

VICE PRESIDENT-ELECTPatricia E. Ganey,

PhD East Lansing, MI

SECRETARYLeigh Ann Burns Naas,

PhD, DABT, ATS, ERT Foster City, CA

SECRETARY-ELECTRuth A. Roberts,

PhD, ATS, FBTS, ERT, FSB, FRCPath Macclesfield, SK

TREASURERGeorge P. Daston,

PhD Mason, OH

PAST PRESIDENTNorbert E. Kaminski,

PhD East Lansing, MI

COUNCILORSAaron Barchowsky,

PhD Pittsburgh, PA

Rosonald R. Bell, MSc, PhD, DABT

Groton, CT

Myrtle A. Davis, DVM, PhD

Rockville, MD

Ofelia A. Olivero, PhD, ATS

Rockville, MD

Tao Wang, MD, PhD, DABT

Emeryville, CA

John A. Wisler, PhD, DABT

San Diego, CA

EXECUTIVE DIRECTORClarissa L. Russell, MBA

Ballot facsimile transmittal

Please Deliver Immediately

To: Debbie Orozco, SOT Ballot Clerk Company: Dixon Hughes Goodman, LLP

Phone: Fax: 240.403.3701

From: Date:

Phone: Very Important: Ballot Reply

Only Ballots faxed by February 1, 2016, will be counted.

Please Fax this page and the Ballot Card to 240.403.3701.Ballot cards faxed to SOT will not be counted.

The following must be completed:

________________________________ Signature ________________________________ Printed Name ________________________________ ________________________________ ________________________________ Address

Society of Toxicology1821 Michael Faraday Drive, Suite 300, Reston, Virginia 20190

Telephone: 703.438.3115 Fax: 703.438.3113 Email: [email protected]

Only Ballots faxed by February 1, 2016, will be counted.

Please Deliver Immediately

Ballot Card

Ballots must be returned with the Ballot transmittal cover page and faxed to Dixon Hughes Goodman, LLP 240.403.3701.

________________________________Printed Name

The following is required:

Society of ToxicologyOfficial Ballot 2016–2017

(Nominees are listed by office, in reverse alphabetical order.)

Society of Toxicology1821 Michael Faraday Drive, Suite 300, Reston, Virginia 20190

Telephone: 703.438.3115 Fax: 703.438.3113 Email: [email protected]

Vice President-Elect(vote for only one)❍ Leigh Ann Burns Naas❍ Matthew S. Bogdanffy❍ _________________________

Treasurer-Elect(vote for only one) ❍ Daland R. Juberg❍ Michael Aschner❍ _________________________

Councilors(vote for no more than two)❍ Richard S. Pollenz❍ Mary Beth Genter❍ PauL M. D. Foster❍ Tammy R. Dugas ❍ _________________________

Awards Committee(vote for no more than three)❍ Courtney E. W. Sulentic❍ John H. Richburg❍ Stephen B. Pruett❍ Terrance J. Kavanagh❍ Michelle J. Hooth❍ Chris Corton❍ Sarah Campion❍ Luisa Camacho❍ _________________________

Membership Committee(vote for no more than four)❍ Martin J. Ronis❍ Reza J. Rasoulpour❍ Lisa E. Tonner Navarro❍ Sharon A. Meyer❍ Kok Wah Hew❍ Kristina D. Chadwick❍ Paul Brown❍ Stacey E. Anderson❍ _________________________

Nominating Committee—From Membership at-Large(vote for only one) ❍ Ian Kimber❍ Daniel R. Dietrich❍ Emanuela Corsini❍ _________________________

Nominating Committee—From Regional Chapters(vote for only one)❍ Alexandros Papanikolaou❍ Pamela J. Lein❍ Jacob Jabbour❍ Jamie C. DeWitt❍ Norman J. Barlow❍ _________________________

Nominating Committee—From Specialty Sections(vote for no more than two)❍ Erik J. Tokar❍ Shashi K. Ramaiah❍ Raegan B. O’Lone❍ John M. Mitchell❍ Kenneth E. McMartin❍ Daniel C. Kemp❍ Jeffery M. Gearhart❍ Linval R. DePass❍ Gary R. Burleson❍ _________________________

________________________________Member’s Signature

1

Biographical Sketches For 2016–2017 Election1821 Michael Faraday Drive, Suite 300, Reston, Virginia 20190

Creating a Safer and Healthier Worldby Advancing the Science of Toxicology

Vice President–Elect (Vote for one of two)Nominees areas listed in reverse alphabetical order.

Vice President-Elect candidates continued on next page 4

SOT-Elected Positions: Secretary-Elect 2013–2014, Secretary 2014–present.

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: CARE Subcommittee 2015–present; Communications Committee, Co-Council Contact 2013–2014; Congressional Subcommittee, Co-Council Contact 2013–2014; Continuing Education Committee 2005–2007; Council Review to Advance Communication (CRAC) 2013–2014; DOD Government Liaison Group 2013–2015, Council Contact and Chair 2014–2015; Historian, Council Contact 2014–present; Issue Statement Review (ISR) Task Force, Council Contact 2015–present; NIEHS Government Liaison Group 2013–2015, Council Contact and Chair 2014–2015; Scientific Program Committee 2009–2013; Toxic Substances Control Act Task Force, Co-Council Contact 2013–2015, Council Contact 2015–present; Michigan Regional Chapter, Councilor 1998–2000; Northern California Regional Chapter 2011–present; Southern California Regional Chapter 2002–present; Women in Toxicology Special Interest Group 2008–present, Councilor 2009–2011; Biotechnology Specialty Section 2009–present, Interim Officer 2009–2010, Councilor 2010–2011; Immunotoxicology Specialty Section 1996–present, Vice President-Elect 2008–2009, Vice President 2009–2010, President 2010–2011, Past President 2011–2012; Regulatory and Safety Evaluation Specialty Section 1996–2001, 2007–present; Risk Assessment Specialty Section 2001; Special Section Collaboration and Communication Group, Co-Chair 2010–2012, Co-Council Contact 2013–2014, Council Contact 2014–present; Colgate-Palmolive Traveling Lectureship in Alternative Methods in Toxicology Award.

Experience: Dr. Burns Naas is Vice President of Drug Safety Evaluation at Gilead Sciences. Prior to Gilead, she was a Drug Safety Therapeutic Area Leader for Antivirals and Infectious Disease (2001–2006) and Oncology (2007–2011) at Pfizer, and was Immunotoxicology Lab Supervisor then Group Leader for Product Toxicology at Dow Corning Corporation (1994–2001). Throughout her career, her work has focused on strategic aspects and the design of safety programs to support chemical product development and registration, and the clinical development and licensure for small molecules and biotherapeutics, including vaccines. Dr. Burns Naas is a member of the editorial board for the International Journal of Toxicology and Journal of Immunotoxicology, and is an Associate Editor for Toxicology Reports. She is currently editing two volumes of Comprehensive Toxicology. She is a former member of the Board of Directors of the American Board of Toxicology and a current member of the Board of Directors of the Academy of Toxicological Sciences. In addition to her activities in the SOT, Dr. Burns Naas has also served in numerous capacities, including as President, for the American College of Toxicology. She has been active in the ILSI HESI Immunotoxicology Technical Committee (2001–2011) and the IQ Consortium (Board of Directors; DruSafe; 2013–present) and has demonstrated a long commitment to promoting advancements in basic and applied toxicology and the impact of toxicological sciences on human and environmental health across multiple scientific organizations and in the literature, and in the training/education of the next generation of toxicologists.

Goals for SOT: Within the membership our career paths and experiences are highly diverse, a reflection of the diverse nature of toxicology itself. In this, we possess the ability to shape the future of the science and practice of toxicology, the central challenge identified in our most recent strategic plan. We are guided by principles such as serving the needs of our discipline and members to make contributions to improving human, animal, and environmental health. Our greatest strength lies in our membership, as does our future. I believe we must focus on continuously growing and evolving the discipline through recruitment, training, and mentoring of students and earlier career scientists. Providing research opportunities is critical and requires that we advocate strongly for continued and enhanced research funding. We need to continue to support forums outside of the Annual Meeting where our scientists can communicate their work and interface with those in other biomedical sciences. We must also recognize the same economic pressures that have affected research funding, have also had an impact on many members of SOT through corporate consolidation and/or reduced budgets which limit professional development opportunities. Therefore, we should strive to provide opportunities to further develop and prepare our members to be able to adapt to changing roles and career paths. One challenge we must continue to address is improving the perception of the discipline of toxicology. This can be done by increasing the understanding by scientists of other disciplines and, critically, non-scientists, of the impact of toxicological sciences on human and environmental health; and actively engaging with diverse disciplines outside of toxicology with the goal of enhancing our collective understanding of disease processes and population dynamics of response. The Annual Meeting is a forum to not only focus on communicating the advances in our discipline but also as a mechanism by which to foster interdisciplinary collaboration. Through this, we can more rapidly incorporate emerging science and technology to increase the impact of toxicology on public and environmental health outcomes and to navigate the frontiers of predictivity and clinical translation.

Leigh Ann Burns Naas PhD, DABT, ATS, ERT

Employer: Gilead Sciences, Inc

Year Joined SOT: 1996

Schools Attended: Medical College of Virginia/Virginia Commonwealth University, PhD, Pharmacology and Toxicology, 1992; Millsaps College, BS, Biology, 1986.

2

Vice President–Elect (Vote for one of two)

SOT-Elected Positions: Councilor 2009–2011; Nominating Committee 2004–2006.

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Endowment Fund Board 2013–present, Co-Chair 2014–2015, Chair 2015-present; ATSDR/NCEH/CDC Government Liaison Group 2010–2011; Communications Strategy Committee 2005–2007; Communications Task Force 2005–2006; Council Subcommittee on Social Networking 2009–2011; Council Subcommittee on SOT Affiliates and Sponsors 2010–2011; Specialty Section Collaboration and Communication Group, Council Contact 2010–2011; Contemporary Concepts in Toxicology Workshop: Use of Genomic Data in Risk Assessment: State-of-the-Art, Steering Committee, 2001; Contemporary Concepts in Toxicology Workshop: Harmonization of Cancer and Non-Cancer Risk Assessment, Co-Chair 1999; Disease Prevention Task Force, Council Contact 2009–2011; Education Committee, Council Contact 2009–2011; Education Summit Organizing Team, Council Contact 2010–2011; EPA Government Liaison Group 2010–2012, Chair 2010–2011; Finance Committee 2002–2005; Issue Statement Review (ISR) Task Force 2013–present; Scientific Program Committee 2006–2009; Task Force to Improve the Scientific Basis of Risk Assessment 2000–2002; Technical Committee 1988–1990; Mid-Atlantic Regional Chapter 1986-2004; Northeast Regional Chapter 2004–present; Biotechnology Specialty Section 2009–present; Carcinogenesis Specialty Section 1986–present, Drug Discovery Specialty Section 2005–present, Immunotoxicology Specialty Section 2015–present;. Mechanisms Specialty Section 1986–present; Regulatory and Safety Evaluation Specialty Section 2004–present; Risk Assessment Specialty Section, Past President 2003–2004, President 2002–2003, Vice President 2001–2002, Vice President-Elect 2000–2001, Councilor 1998–2000.

Experience: Dr. Bogdanffy has 29 years of SOT membership and service and over 38 years of research and practice in the field of toxicology including experience in chemical, agrochemical, pharmaceutical and consumer products industries. He began his career as a toxicology technician with Avon Products, became Research Manager and Director of Biochemical and Molecular Toxicology at DuPont Haskell Laboratory and is currently Director, Regulatory Toxicology, at Boehringer Ingelheim Pharmaceuticals. He has oversight for all nonclinical safety project team representatives, nonclinical safety strategies, and delivery of safety assessments and regulatory submissions from preclinical development through market authorization. He has served on peer and grant review boards for TERA, US EPA, NRC, and DOE. He is a member of the ILSI HESI Emerging Issues Subcommittee and has served on numerous industrial consortia including the American Chemistry Council and the Pharmaceutical Manufacturers Association where he is currently a member of the Clinical and Preclinical Development Committee. Dr. Bogdanffy has authored more than 85 publications in toxicology and risk assessment, has served on the editorial boards of several journals including Associate Editor for Toxicological Sciences. He has had research collaborations with academia and is an Adjunct Associate Professor at the University of Connecticut School of Pharmacy. He is a member of the American College of Toxicology, diplomate of the American Board of Toxicology, and is a Fellow and Vice President of the Academy of Toxicological Sciences.

Goals for SOT: The Society of Toxicology enjoys an important position of responsibility within our profession. We are the world’s largest professional society of toxicologists. Our mission to create a safer and healthier world by advancing the science and increasing the impact of toxicology sets a high bar for the work that is in front of us. As the future President of SOT, my goals are to 1) grow our global membership, 2) engage our component groups, 3) advocate for research and education, and 4) maintain our fiscal health.

Our broad membership is our most important asset. Advancing global access to our Society brings further diversification of our scientists and the scientific issues we address. When SOT was founded in 1961, the issues of today could hardly have been envisioned. Yet SOT scientists are working on environmental health concerns that span the globe and the development of new, safer products that are reaching the global marketplace.

We must recognize and enable the Specialty Sections, Special Interest Groups, and Regional Chapters (Component Groups) as grassroots energizers for SOT programs and initiatives. Today, these vital groups form the integrated network of scientific and social interests that is the heart of our Annual Meeting and year-round affiliated activities. Cutting-edge toxicological science, professional networking, and educational opportunities make our meetings great but depend upon the growing importance of the component groups.

Critically important to our mission is advancing the science of toxicology and risk assessment. As stated in the NAS report on toxicology in the 21st century, our science is approaching a pivot point. Through innovative discoveries and application of emerging technologies, SOT has and will continue to transform and advance new scientific tools that improve and inform risk assessment. To this end, SOT must invest significant effort to support basic and applied research and to provide a forum for life-long education and training.

SOT is vibrant and financially sound. Effective leadership, fiscal responsibility, creative approaches to revenue generation, and a strong endowment fund make possible travel awards, grants, outreach, educational, and many other important initiatives. SOT must continue to maintain a strong balance sheet, while effectively using revenues and reserves for the benefit of our membership and the pursuit of our mission.

With your support, I will work with Council to accomplish these goals, stay focused on our mission, and lead the Society successfully into the next strategic period. Through the collegial dynamic of our academia, government, and industry sectors, a hallmark of our excellence, the dedication of our voluntary membership and our leading science, we are well positioned to deliver on our mission.

Matthew S. Bogdanffy PhD, DABT, ATS

Employer: Boehringer Ingelheim Pharmaceuticals, Inc.


Schools Attended: Chemical Industry Institute of Toxicology, Postdoctoral Fellow, 1986; Northeastern University, PhD, Toxicology, 1984; Springfield College, BS, Chemistry and Biology, 1980.

3

Treasurer-Elect candidates continued on next page 4

Treasurer-Elect (Vote for one of two)

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Contemporary Concepts in Toxicology Organizing Committee for FutureTox III: Bridges for Translation, Chair 2014–present; Communications Committee 2008–2010, Chair 2009–2010; Congressional Subcommittee 2008–2014, Chair 2008–2009; Contemporary Concepts in Toxicology Conferences Committee 2012–2015; Gulf Oil Spill Working Group 2011–2012; Regulatory Affairs and Legislative Assistance Committee 2006–2009, Chair 2007–2009; SOT Congressional Task Force 2014–2015; Toxic Substances Control Act Task Force, Chair 2010–2015; Lake Ontario Regional Chapter 2001; Ohio Valley Regional Chapter 2003; Biotechnology Specialty Section 2010–present; Regulatory and Safety Specialty Section 2006–present, Vice President-Elect 2011–2012, Vice President 2012–2013, President 2013–2014, Past President 2014–2015; Risk Assessment Specialty Section 1998–2006; Reproductive and Developmental Specialty Section Outstanding Research Award 1991 and 1992; Robert L. Dixon Award 1992.

Experience: Dr. Juberg is the Global Leader of the Human Health Assessment function within Regulatory Sciences/R&D at Dow AgroSciences (IN). Preceding this was his appointment as North American Leader of HHA (2010–2014), having joined Dow AgroSciences in 2002 as a Senior Toxicologist. Current responsibilities include leading a global 30+ member team supporting toxicology, exposure/risk assessment and residue chemistry activities in support of sustainable agricultural chemistry and seeds/traits platforms, using TT21C approaches and advances in the toxicological/biological sciences. He was a Principal with the International Center for Toxicology and Medicine (Washington, DC) from 1999–2002, product toxicologist for Eastman Kodak Company (NY) from 1992–1999, and environmental scientist with Encotec (MI) from 1984-1987.

In addition to his SOT leadership roles, Dr. Juberg has served as the Chair of ISLI TF10 on protein safety/whole food testing, led the creation and implementation of the first multi-stakeholder conference on endocrine modulators and Tier 1 Test results, and co-chaired the ILSI TF on Adverse/Adaptive Effects. Dr. Juberg has served as an editor and peer reviewer for professional society journals and government agency publications and has participated at State and National levels in matters involving environmental and human health, including leadership of multiple SOT Congressional briefings and testimony before the Indiana State Legislature on the role of toxicology and biomonitoring in environmental health evaluation. He works to engage diverse stakeholders and achieve consensus and common ground when leveraging applied toxicology and robust science as the underpinnings of sound science policy within legislation/regulation. He was elected as a Fellow of the Academy of Toxicological Sciences in 2012.

Goals for SOT: A highlight of my career has been my association with the Society of Toxicology which has resulted in strong professional relationships and a common bond with SOT members to embrace and promote the vision of the Society. Because much of my professional life has involved the application of toxicological sciences within regulatory science frameworks, I have appreciated the opportunity to serve in leadership roles for the Society that has enabled me to work with a diversity of members to bring toxicology into important legislative and regulatory discussions. I am committed to continuing this journey through inclusive and consensus-building leadership that is based on member voice across sectors and stakeholder groups as we work to achieve the mission of the Society.

My first goal is to work to maintain a strong, viable, and influential scientific society, so that it can realize its 2015–2018 strategic goals while focusing on member needs, growth, and influence in the scientific community. It is of paramount importance that we devote attention and commit resources to continue the development of the next generation of toxicology practitioners and leaders across the globe so that we have a strong base going forward. I am committed to supporting TT21C approaches and tools and hope that across sectors we embrace this transformation to advance the science while committing to the 3 R’s associated with animal testing. At a time when science is sometimes marginalized in public discussions and decision-making, there are critical areas where the Society and its members can play an increasing role in advocating for the application of the science and its principles. To this end, I would like to work with fellow SOT members to make the science of toxicology increasingly visible, relevant, and useful in public health discussions and regulatory decision-making. Underpinning this increasing reliance on the SOT as a trusted and valued voice is an aspiration to seek for our members key opportunities and avenues for practicing, educating, and leading with our science.

A strong society with clearly defined goals and forward-looking strategy is dependent on sound financial footing and as Treasurer of the Society (and Chair of the Finance Committee) I will work to ensure fiscal responsibility and accountability and seek to create additional mechanisms by which the Society can grow its financial base. I hope to work with fellow Council members to prioritize opportunities and fund key initiatives that will support local, national, and international efforts aimed at increasing the impact of toxicology in public health protection, science policy, and regulatory decision-making.

Daland R. Juberg PhD, ATS

Employer: Dow AgroSciences, LLC.


Schools Attended: The University of Michigan, PhD, Toxicology, 1992; The University of Michigan, MS, Environmental Health Sciences, 1984; Wittenberg University, BA, Biology, 1983.

4

Treasurer-Elect (Vote for one of two)

Michael Aschner PhD, ATS

Employer: Albert Einstein College of Medicine


Schools Attended: University of Rochester, School of Medicine, Postdoctoral Fellow, Toxicology, 1987; University of Rochester, School of Medicine, PhD, Neurobiology/Anatomy, 1985; University of Rochester, School of Medicine, MS, Anatomy, 1983; University of Rochester, BS, Natural Sciences, 1980.

SOT-Elected Positions: Awards Committee 2014–present.

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Placement Committee 1992–1995, Chair 1994–1995; Research Funding Committee 2010–2013; Scientific Program Committee 2007–2010; Metals Specialty Section 1986–2006; Neurotoxicology Specialty Section 1986–present, Secretary/Treasurer 1992–1994, Vice President-Elect 1995–1996, Vice President 1996–1997, President 1997–1998, Councilor 1998–1999; North Carolina Regional Chapter 2004–2005; Southeastern Regional Chapter 2010–2012.

Experience: Dr. Aschner has served on numerous national and international toxicology panels (Institute of Medicine, US Environmental Protection Agency, Center for Disease Control), served and chaired the Neurotoxicology and Alcohol (NAL) National Institutes of Health Study Section, and authored approximately 500 peer-reviewed manuscripts and chapters in the area of neurotoxicology. He serves as Editor (NeuroMetals) and Associate Editor (Neurotoxicology; Toxicological Science; Neurochemistry Research; Biology Trace Elements Research) and on several other editorial boards. He is a member of the Society of Toxicology (since 1986), Society for Neuroscience, a Fellow of the Academy of Toxicological Sciences, and a Past President of the International Neurotoxicology Association. In 2011, he was the recipient of the Society of Toxicology Merit Award, and in 2013 he was elected as Fellow of the American Association for the Advancement of Science (AAAS). He presently also serves as President of the International Society of Trace Elements Research in Humans. Dr. Aschner directed several large research programs including a P30 (center grant in Molecular Toxicology), the MHRP (Manganese Health Research Program, supported by the Department of Defense), and a T32 Training Grant in Molecular Toxicology.

Goals for SOT: My goals will be to maintain the financial health of the SOT and expand corporate financial support. I will closely consult with Council attending to the annual budget and the management of the Society’s bank accounts and other financial matters. In cooperation with Council, one of my goals is to develop new opportunities for funding mechanisms for investigators, by furthering philanthropic corporate resources.

5

Councilors candidates continued on next page 4

Councilors (Vote for no more than two of four)

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Contemporary Concepts in Toxicology Conferences Committee 2012–2013; Education Committee 2012–2015, Co-Chair 2013–2014, Chair 2014–2015; Education Subcommittee: Graduate Education 2013–2015; Education Subcommittee: ToxLearn Work Group 2014–2015; Education Subcommittee: Undergraduate Education 2013–2014; Scientific Program Committee 2008–2012; Southeast Regional Chapter 2002–present; Mechanisms Specialty Section 2005–present; Molecular Biology Specialty Section 1998–present, Councilor 2003–2005, Vice President-Elect 2005–2006, Vice President 2006–2007, President 2007–2008, Past President 2008–2009, Student Poster Awards Committee Chair, 2002–2005.

Experience: Dr. Pollenz was a faculty member at the Medical University of South Carolina prior to becoming faculty at the University of South Florida in 2000. His research has been funded by NIEHS and resulted in numerous peer-reviewed manuscripts on aspects of molecular toxicology that include studies of gene regulation and protein degradation mediated by environmental chemicals such as TCDD. He was named a Fellow to the American Association for the Advancement of Science (AAAS) in the field of molecular pharmacology in 2013. Dr. Pollenz served as Associate Dean in the USF Graduate School between 2008–2011 where he developed innovative professional development workshop for STEM graduate students to assist in job readiness. He now serves USF as an Associate Dean within Undergraduate Studies as the Director of the Office for Undergraduate Research. In this role he has increased the capacity of positions and developed models for the integration of research into the curriculum. These initiatives have been presented at several AACU meetings. He is currently Director of a multi-year science education grant from HHMI and he continues to research innovations in teaching and learning designed to increase undergraduate student persistence and academic progression in the STEM disciplines.

Goals for SOT: SOT is a very unique Society with extensive membership across all job sectors. This feature is extremely valuable as the nation looks to how we will train and prepare the STEM workforce to meet the challenges during the next 10–20 years. My vision for SOT is to become a leading society and innovator in how we prepare our students and postdoctoral scholars to integrate into the workforce especially at it relates to education, outreach and collaboration between academia, government and industry.

Richard S. Pollenz PhD

Employer: University of South Florida


Schools Attended: Northwestern University, PhD, Cell and Molecular Biology, 1991; Philadelphia College of Pharmacy, BS, Toxicology, 1983.

6


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Education Summit Organizing Team 2010–2012; Job Market Survey Subcommittee 2010–2012; Placement Committee 2000–2003; Professional Needs Assessment Task Force 2009–2012, Chair 2010–2012; Scientific Program Committee 2012–2016; North Carolina Regional Chapter, Councilor 1994–1996; Ohio Valley Regional Chapter 2002–present, Councilor 2006–2008, Vice President 2008–2009, President-Elect 2009–2010, President 2010–2011, Past President 2011–2012; Inhalation Specialty Section 1997–2002; Neurotoxicology Specialty Section 1994–present; Toxicologic and Exploratory Pathology Specialty Section 2000–present.

Experience: Dr. Genter followed her graduate studies in neurotoxicology with a postdoctoral fellowship at the Chemical Industry Institute of Toxicology. Her first academic position was in the Department of Toxicology at North Carolina State University. Her position there included research, teaching, and service as the toxicologist for the North Carolina Cooperative Extension Service. Dr. Genter joined the Department of Environmental Health at the University of Cincinnati in 1999 and is currently a full professor. Her research interests and expertise include extrahepatic biotransformation; olfactory epithelial biology and toxic responses; and intranasal drug delivery.

Goals for SOT: My overarching concern, for which I hope to be able to make a significant positive difference, is training of PhD students to be competitive in the current job market. Most students graduate with their PhD degree as excellent researchers; however, they often lack knowledge of career tracks other than academic research. As a consequence, some PhD toxicologists may do one or more very long postdoctoral fellowships, after which they finally attain an academic position, or, unfortunately, find that they must seek another career altogether. Therefore, I want to facilitate dissemination of knowledge of other career opportunities for PhD toxicologists early in the training of PhD students and to implement programs to develop the necessary skill sets to be competitive for any career in toxicology.

Mary Beth Genter PhD, DABT, ATS

Employer: University of Cincinnati


Schools Attended: Duke University, PhD, Toxicology/Pathology, 1988; St. Lawrence University, BS, Biology/Chemistry, 1984.

7

Councilors candidates continued on next page 4


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Continuing Education Committee 1996–1999, Chair 1998–1999; Scientific Program Committee 2009–2013; Reproductive and Developmental Toxicology Specialty Section 1987–present, Vice President-Elect 1997–1998, Vice President 1998–1999, President 1999–2000, Past President 2000–2001.

Experience: Dr. Foster is the Chief of the Toxicology Branch within the Division of the National Toxicology program (NTP) headquartered at the National Institute of Environmental Health Sciences (NIEHS) in Research Triangle Park, North Carolina. The Toxicology Branch is responsible for the scientific leadership of the NTP’s cancer and non-cancer toxicology testing Program. Prior to joining NIEHS in 2002, he was the Director of the research program in endocrine, reproductive and developmental toxicology at the CIIT Centers for Health Research (CIIT). He joined CIIT in December 1995 after a 13-year career at Zeneca’s (formerly Imperial Chemical Industries) Central Toxicology Laboratory in Cheshire, England, where he was head of Reproductive and Developmental Toxicology. He was presented with the European Society of Toxicology’s young scientist award in 1988 for his work on testicular toxicity and has been awarded four NIH Merit awards and an EPA Bronze star. Dr. Foster is a Fellow of the Academy of Toxicological Sciences (ATS) and was elected to the Board of Directors in 2014 and currently serves as the Secretary/Treasurer. He serves on the editorial boards of a number of journals and is a former Associate Editor of Toxicological Sciences (1998–2005). Dr. Foster is internationally recognized for his expertise in developmental and reproductive toxicology and endocrine disruption and has served on a number of international and national (including NRC/NAS) committees in these areas of toxicology. He is the author or co-author of more than 130 peer-reviewed publications and book chapters, including 5 of the top 50 most cited papers (3 in the top 10) in Toxicological Sciences and numerous regulatory study reports.

Goals for SOT: I am immensely gratified and honored at being selected to run for the office of Councilor in the Society of Toxicology. Having worked during my career in toxicology in a research institution, industry and now the federal government (a true “poacher turned gamekeeper”) I have come to realize how important it is that SOT provides a welcoming venue of high quality scientific meetings that are fit for purpose and that appeal to all the various SOT constituents. Indeed, my time on the SOT Program Committee has indicated how difficult such a task is to achieve on a regular basis. My vision for SOT is to maintain its preeminent position in the field of toxicology globally; to recognize and address the disparate needs of its membership both in the US and internationally, both within the Society and at our Annual Meetings and also to continue to promote the important role that trainees and students have in our Society—the very future and growth of our learned society depends upon it. Lastly, I would endeavor to do this with a sense of humor! The collegial and interactive nature of SOT is something that is a strength of our society and needs to be maintained, if not improved upon.

Paul M. D. Foster PhD, ATS

Employer: NIEHS-NTP


Schools Attended: National Foundation for Cancer Research (UK), Postdoctoral Fellow, 1977–1978; Brunel University, Uxbridge UK, PhD, Biochemistry/Toxicology, 1977; Brunel University Uxbridge, UK, BSc (hons), Applied Biochemistry, 1974.

8


SOT-Elected Positions: Nominating Committee 2009–2011.

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Career Resource and Development Committee 2014–2015; Education Subcommittee: ToxLearn Work Group 2006–present; Research Funding Committee 2013–2014; Gulf Coast Regional Chapter 2002; South Central Regional Chapter 2001–present, Councilor 2002, Secretary 2003–2005, Vice President-Elect 2005–2006, Vice President 2006–2007, President 2007–2008, Past President 2008–2009; Women in Toxicology Special Interest Group 2004; Cardiovascular Toxicology Specialty Section 2010–present, Secretary/Treasurer 2011–2012, Secretary 2012–2013, Vice President-Elect 2014–2015, Vice President 2015–present, Chair of the Awards Committee, Chair of the Membership Committee; Mechanisms Specialty Section 2010–2014; Medical Device and Combination Product Specialty Section 2011–present.

Experience: Dr. Dugas is a Professor of Comparative Biomedical Sciences at the Louisiana State University School of Veterinary Medicine. Her research is focused on the role of the environment and environmental factors in the induction of vascular diseases such as atherosclerosis. She also co-founded a biotech startup aimed at the development of endovascular medical devices. She has been active in SOT since 2000 and has been involved in number of Society activities. As President of the South Central Chapter, her focus was on increasing the involvement of undergraduate researchers in Chapter activities, as well as the visibility of toxicology research among high school students. Specifically, she initiated Chapter programs to fund the travel of undergraduate researchers to Chapter meetings, Undergraduate Presentation Awards, as well as SOT Special Awards to high school students at regional and state science fairs across three states. In addition to these Regional Chapter activities, since 2006, she has been involved in the ToxLearn Working Group. The focus of this group is the development of an online introductory toxicology course hosted by the National Library of Medicine. Finally, Dr. Dugas has been actively engaged in the Cardiovascular Toxicology Specialty Section, where she served in numerous officer roles on the Executive Committee, as well as Chair of several committees.

Goals for SOT: My interests are in expanding the visibility of toxicology and its importance among our communities, our peers in research, and among undergraduates.

Tammy R. Dugas PhD

Employer: Louisiana State University School of Veterinary Medicine


Schools Attended: University of Texas Medical Branch, Postdoctoral Fellow, Toxicology, 2001; Drexel University College of Medicine, Postdoctoral Fellow, Biochemistry, 1998; Louisiana State University, PhD, Chemistry, 1996; Louisiana State University, BS, Biochemistry, 1992.

9

Awards Committee candidates continued on next page 4

Awards Committee (Vote for no more than three of eight)

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Career Resource and Development Committee 2010–2013, Co-Chair 2011–2012, Chair 2012–2013; Continuing Education Committee 2007–2010; Education Summit Organizing Team 2010–2012; Mentoring Breakfast Planners 2013–2014; Women in Toxicology Mentoring Initiative 2012-2013; Ohio Valley Regional Chapter 2002–present, Secretary 2006–2009, Vice President 2009–2010, President-Elect 2010–2011, President 2011–2012, Past President 2012–2013; Regional Chapter Collaboration and Communication Committee and Education/Outreach Liaison 2011–2013; Women in Toxicology Special Interest Group 1995–present; Immunotoxicology Specialty Section 1996–present; In Vitro and Alternative Methods Specialty Section 2015–present; Inhalation and Respiratory 2013–2015; Molecular Biology Specialty Section 2006–present.

Experience: Dr. Sulentic is currently an Associate Professor within the Department of Pharmacology and Toxicology at Wright State University, Boonshoft School of Medicine. Prior to joining the faculty at Wright State in November 2003, she was a postdoctoral Fellow in the laboratory of Dr. Norbert Kaminski at Michigan State University and was funded under an NIEHS National Research Service Award. She has received funding for her research from NIEHS, several intramural grants and the Colgate-Palmolive Grant for Alternative Research from SOT. Her overall research goal is to elucidate, at the cellular and molecular level, the human health implications of altered antibody expression by xenobiotics such as the environmental contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin, and the role of specific genetic factors in influencing individual susceptibility to xenobiotics. Dr. Sulentic has been very active in training undergraduate and graduate students and has become highly involved in professional societies including the American Society for Pharmacology and Experimental Therapeutics, the American Association of Immunologist, and particularly SOT and the Ohio Valley Regional Chapter.

Goals for SOT: My previous service on several SOT committees and outreach efforts has allowed me an opportunity to contribute to initiatives directly supporting the mission and guiding values of the Society. From this perspective, the Awards Committee plays a key role in implementing several strategic priorities of the Society, from supporting the efforts of beginning scientists through travel awards and research/training funds to acknowledging the service and achievement of scientists who exemplify the values of the Society. It would be a great honor to serve as a member of the Awards Committee and if elected, my main objectives would be to ensure diversity (i.e. gender, ethnic, and institutional) and actively solicit nominations of members who exemplify the overall mission and values of the Society.

Courtney E. W. Sulentic PhD

Employer: Wright State University


Schools Attended: Michigan State University, PhD, Pharmacology and Toxicology, 1999; Lake Superior State University, BS, Biology, 1992.

10


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Committee on Public Communications 2001–2004; Gulf Coast/Lone Star Regional Chapter 2002–present, Councilor 1999–2000 and 2003–2005, Treasurer 2000–2004; Immunotoxicology Specialty Section 2012–present; Mechanisms Specialty Section 1998–present, Councilor 2003–2005; Metals Specialty Section 2012–present; Molecular and Systems Biology Specialty Section 1998–present; Reproductive and Developmental Toxicology Specialty Section 1998–present; Toxicologic and Exploratory Pathology Specialty Section 2014–present; Junior Councilor & Organizer of Carl C. Smith Student Awards.

Experience: Dr. Richburg, the Gustavus and Louise Pfeiffer Professor in Toxicology, currently serves as the Associate Dean for Research and Graduate Studies in the College of Pharmacy at The University of Texas at Austin. Previously Dr. Richburg served as the Head of the Division of Pharmacology and Toxicology (2004–2015) and also served as the Director of the Center for Molecular and Cellular Toxicology (2005–2015). Since 2003, Dr. Richburg has been serving as the Director of the longstanding NIH/NIEHS-supported T32 pre- and postdoctoral toxicology-training program (T32 ES07247). Dr. Richburg also is an Adjunct Professor in the Department of Epigenetics and Molecular Carcinogenesis of the UT MD Anderson Cancer Center-Science Park (UTMDACC-SP). The longstanding focus of Dr. Richburg’s research program is to decipher the molecular and cellular mechanisms by which exposure to certain environmental (e.g., phthalate acid ester-based plasticizers) or clinical chemotherapeutic agents (e.g., cisplatin) can result in disruption of male reproduction. The long-term goal of this research is to provide molecular and cellular insights on toxicant action that will be useful for predicting and preventing human reproductive health risks to both chemotherapeutic agents as well as chemicals found in the environment. Dr. Richburg has had near continuous NIEHS grant funding to support his work with the phthalate compounds during the last 18 years.

Goals for SOT: I attended my first Annual Meeting of the Society of Toxicology held in Washington, DC in 1987 during my final year in the toxicology undergraduate program at Northeastern University. Since that time, with few exceptions, I have attended and participated in each of the Annual Meetings of the Society. I consider the SOT my “home” scientific institution and its mission of “creating a safer and healthier world by advancing the science and increasing the impact of toxicology” matches that of my own professional mission. Over the last 28 years of participating in SOT events, I have a good sense of the membership and therefore feel well qualified to serve on the Awards Committee of the SOT. My goal is to nominate well-qualified SOT members who will actively support the SOT mission and to facilitate the education and development of its members to be able to expertly address the complex challenges in toxicology that society is facing today.

John H. Richburg PhD

Employer: The University of Texas at Austin


Schools Attended: Rutgers, The State University of New Jersey/University of Medicine and Dentistry of New Jersey, PhD, Toxicology, 1993; Northeastern University, BS, Toxicology, 1987.

11



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Education Committee 2008–2011; Education Subcommittee: Undergraduate Education 2009–2010; South Central Regional Chapter 2002–present, Councilor 1996–1997 and 2003–2004, Treasurer 1998–2000, Vice President 2001–2002, President 2002–2003, Organizing Committee for the Fall Meeting 2004; Biological Modeling Specialty Section 2010; Immunotoxicology Specialty Section 1991–present, Councilor 1997–1999, Secretary/Treasurer 2003–2005, Vice President-Elect 2005–2006, Vice President 2006–2007, President 2007–2008; Immunotoxicology Specialty Section 1991–present, Awards Committee Chair 2000–2001, Program Committee Chair 2005–2006.

Experience: As Councilor for the Immunotoxicology Specialty Section, Dr. Pruett served as Chair of the Awards Committee. Therefore, he is familiar with this process. In addition, as President of the Specialty Section, he chaired the selection of the winner of the most prestigious award, the Career Achievement Award. As Vice President of the Immunotoxicology Specialty Section, Dr. Pruett served as Chair of the Program Committee for the Specialty Section. Dr. Pruett has served on NIH review panels (at least one per year) since 1992, which has given him experience in evaluating applications for particular criteria and making difficult choices. This also gave him experience in building consensus and listening carefully and objectively to the opinions of others. He has learned similar skills serving for the last 8 years as head of a diverse department in a College of Veterinary Medicine, particularly in the tenure and promotion process. Finally, Dr. Pruett has been selected as a Fellow of Academy of Toxicological Sciences and served for several years on the editorial board of Toxicological Sciences (until this year), Toxicology and Applied Pharmacology (active), and the Journal of Immunology (ending two years ago).

Goals for SOT: The mission statement of SOT is excellent. All aspects of this mission are enhanced when we recognize and publicize top level performance and accomplishments with prestigious awards. As a member of the Awards Committee, I would seek to identify candidates whose work has had a major impact in toxicology. I also would support increased emphasis on making the public aware of these awardees and their work as a way of making the public more aware of the value of toxicologists to society.

Stephen B. Pruett PhD

Employer: Mississippi State University


Schools Attended: Medical College of Virginia, Sabbatical, Toxicology, 1990; Louisiana State University Health Sciences Center, Shreveport, PhD, 1980; Northwestern State University of Louisiana, BS, 1976.

12


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Pacific Northwest Regional Chapter 1994–present, Councilor 1994–1995 and 1998–1999, Vice President-Elect 1995–1996, Vice President 1996–1997, President 1997–1998; Cardiovascular Toxicology Specialty Section 2012–present; Immunotoxicology Specialty Section 1991–present; In Vitro and Alternative Methods Specialty Section 1996; Inhalation and Respiratory Specialty Section 2009–present; Mechanisms Specialty Section 1991–present, Councilor 2006–2008, Vice President-Elect 2011–2012, Vice President 2012–2013, President 2013–2014, Past President 2014–2015; Nanotoxicology Specialty Section 2009–present; Toxicologic and Exploratory Pathology Specialty Section 2009–present.

Experience: Dr. Kavanagh received a BS in Natural Resources from the University of Michigan, an MS in Physiology/Toxicology, and a PhD in Toxicology and Genetics from Michigan State University. He conducted research in free radical biology and aging as a postdoctoral Fellow at the University of Washington. Dr. Kavanagh joined the faculty at the University of Washington as a Research Assistant Professor in the Departments of Medicine and Environmental Health in 1989. He is currently Professor in the Department of Environmental and Occupational Health Sciences and Adjunct Professor of Pulmonary and Critical Care Medicine at the University of Washington. Dr. Kavanagh is a Diplomate of the American Board of Toxicology and a member of the Society of Toxicology, the Society for Redox Biology and Medicine, the International Society for Analytical Cytology, and the Society for Environmental Toxicology and Chemistry. Dr. Kavanagh’s areas of research include glutathione metabolism, molecular toxicology, analytical cytology, free radical biology, oxidative stress biomarkers, toxicogenomics and nanotoxicology. Dr. Kavanagh is currently Director of the UW Center for Ecogenetics and Environmental Health, and Director of the UW Nanotoxicology Center. Dr. Kavanagh has authored more than 150 peer-reviewed scientific articles, book chapters or other scholarly works.

Goals for SOT: I am honored to be considered as a candidate for the Society of Toxicology’s Awards Committee. I have been active in SOT for 25 years, and have been active at the regional level (Pacific Northwest Association of Toxicologists, Councilor, President) and in Specialty Sections (Mechanisms, Councilor, President; Immunotoxicology; Cardiovascular Toxicology; Inhalation and Respiratory, Nanotoxicology, Toxicologic and Exploratory Pathology). SOT is composed of a highly interdisciplinary and talented membership, with affiliations in academia, government, industry and not-for-profit entities. As such, we have a very rich and diverse membership, all of whom deserve to be considered in the awards process. Regarding the selection of SOT awardees, it is my view that we need to consider a nominee’s scientific contributions, their service to the SOT and the broader scientific community, and their dedication to the principle that SOT has an important role in ensuring the health and well being of all people. I will do my best to foster an atmosphere of fairness and cooperation among members of the Awards Committee, and will advance the values of excellence, honesty and integrity as important criteria in the awardee selection process. I look forward to serving the SOT in this capacity and would be entirely grateful for your support.

Terrance J. Kavanagh PhD, DABT

Employer: University of Washington


Schools Attended: Michigan State University, PhD, Environmental Toxicology and Genetics, 1985; Michigan State University, MS, Wildlife Toxicology/Physiology, 1980; University of Michigan, BS, Natural Resources/Wildlife Managment, 1975.

13



SOT-Elected Positions: Membership Committee 2012–2015.

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Committee on Diversity Initiatives 2004–2006, Co-Chair 2004–2005, Education Liaison 2005–2006; Continuing Education Committee 2009–2010; Education Committee 2004–2007, Chair 2006–2007; North Carolina Regional Chapter 1990–present, Councilor 2003–2005; Women in Toxicology Special Interest Group 2003–present, Vice President 2001–2002, President 2002–2003, Past President 2003–2004; Carcinogenesis Specialty Section 1999–present, Councilor 2006–2008.

Experience: Dr. Hooth is currently the Chief of the Program Operations Branch in the Division of the National Toxicology Program (DNTP) at the National Institute of Environmental Health Sciences. The Program Operations Branch provides scientific and information technology expertise for a number of functions in support of NTP research efforts. Prior to assuming this leadership role, she served as a project leader in the Toxicology Branch, DNTP, where she designed and reported a broad array of toxicological studies for test articles including metals, herbals, drinking water disinfection by-products and contaminants, and industrial compounds. Dr. Hooth received a BS in Biological Sciences from Michigan State University in 1990 and a PhD in Toxicology from the University of North Carolina at Chapel Hill in 1996. She completed postdoctoral training at the US Environmental Protection Agency. She joined the NTP/NIEHS in 2000 and became a Diplomate of the American Board of Toxicology in 2003. Her contributions to the Society include serving as a Councilor in the North Carolina Regional Chapter, as a Councilor in the Carcinogenesis Specialty Section and as a chair/member of several other committees. She was a founding member of the Women In Toxicology Special Interest Group and worked to establish WIT awards that recognized the accomplishments of women toxicologists within SOT and to nominate women toxicologists for other SOT and national awards.

Goals for SOT: As a Society, it is important that we continue to raise public awareness of SOT as a source of reliable and credible information and data and to promote the public and environmental health impact of toxicological research. We can accomplish this by expanding our membership from the US and other countries, encouraging active participation in Society activities and developing resources and tools to communicate effectively with a variety of audiences. We can also increase the stature of the Society by recognizing the significant accomplishments of our members. As a member of the Awards Committee, I would work to maintain the high quality of the award recipients and ensure that we recognize the diverse scientific and leadership achievements of our members and others who have contributed significantly to the field of toxicology. This includes consideration of nominees from diverse scientific disciplines, sectors of employment, geographical areas (both nationally and internationally) and levels of professional experience.

Michelle J. Hooth PhD, DABT

Employer: NIEHS-NTP


Schools Attended: University of North Carolina at Chapel Hill, PhD, Toxicology, 1996; Michigan State University, BS, Biological Sciences, 1990.

14


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Contemporary Concepts in Toxicology Conferences Committee 2010–2013, Co-Chair 2011–2012, Chair 2012–2013; Continuing Education Committee 2006–2009, Chair 2008–2009; Leadership Strategy Committee 2008–2009; Scientific Liaison Coalition 2011–2013; North Carolina Regional Chapter 2001–present; Carcinogenesis Specialty Section 1998–present, Secretary/Treasurer 2006–2008; Molecular and Systems Biology Specialty Section 1998–present, Vice President-Elect 2010–2011, Vice President 2011–2012, President 2012–2013, Past President 2013–2014, Specialty Section Collaboration and Communication Group 2012–2014; AstraZeneca Traveling Lectureship Award 2010.

Experience: Dr. Corton is a Senior Research Biologist in the National Health and Environmental Effects Research Laboratory at the US Environmental Protection Agency. He received his PhD degree in Biochemistry from University of Kansas Medical Center followed by a postdoctoral research fellowship at Duke University in yeast molecular biology. From 1989 to 2002, he was a staff scientist at CIIT in Research Triangle Park, North Carolina (now Hamner Institute). In 1994–1995 he was a visiting scientist in the “Orphan Nuclear Receptor” group at Karolinska Institutet, Stockholm, Sweden. His main area of research is nuclear receptor mode-of-action and advancing the use of toxicogenomics in human risk assessment. He holds editorial board appointments for six journals including Toxicological Sciences, is the North American Editor for the journal Nuclear Receptor Research and is past Co-Editor of PPAR Research. He has been a reviewer and/or chair on over 30 peer review committees for NIH/NIEHS grants. Since 1998 when joining SOT, Dr. Corton has been an active member including organizing and co-chairing many SOT symposia, workshops, and CE courses and serving as member and Chair of the Continuing Education and Contemporary Concepts in Toxicology Committees. In 2010, he was the recipient of the AstraZeneca Traveling Lectureship award. He has co-authored more than 100 papers, reviews, and book chapters.

Goals for SOT: The Society of Toxicology awards are an important facet of the Society. They recognize excellence and demonstrate to the membership and the outside scientific community that within our Society hard work is not only respected but rewarded. My overall philosophy regarding the awards is an extension of the SOT Strategic Plan: promote and award efforts that use 21st century integrative approaches including systems-level analysis that provide ground-breaking insights into mechanisms of chemical toxicity; promote efforts to award the accomplishments of under-recognized minorities as well as students and postdoctoral research fellows; and ensure the candidates follow the Society’s highest standards of ethics and professional excellence.

Chris Corton PhD

Employer: US EPA


Schools Attended: Duke University, Postdoctoral Fellow, Molecular Biology, 1987–1989; University of Kansas Medical Center, Postdoctoral Fellow, Bacteriology, 1984–1987; University of Kansas Medical Center, PhD, Biochemistry, 1984; Grinnell College, BA, Chemistry, 1979.

15



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Postdoctoral Assembly Executive Board 2009–2011, Co-Chair 2009–2010, Chair 2010–2011; SOT ToXchange Task Force 2011–2014; Student Advisory Council: Regional Chapter/Special Interest Group Grad Committee 2008–2009; Website Task Force, Chair 2014–2015; Northeast Regional Chapter 2011–present, Vice President 2011–2012, President 2012–2013, Past President 2013–2014; Women in Toxicology Special Interest Group 2008–present, Postdoctoral Representative 2008–2009; Mechanisms Specialty Section 2010–present; Reproductive and Developmental Toxicology Specialty Section 2008–present, Junior Councilor 2012–2014, Councilor 2015–present; Mixtures Specialty Section Best Student/Postdoc Abstract Award 2010; Northeast Regional Chapter Fall Meeting Student Poster Award 2007; Northeast Regional Chapter Student Travel Award for SOT Annual Meeting 2008; Reproductive & Developmental Toxicology Specialty Section Travel Award 2009 and 2010.

Experience: Dr. Campion is currently a Senior Principal Scientist in the Developmental and Reproductive Toxicology group at Pfizer Worldwide Research and Development. She received her PhD in Pharmacology and Toxicology from the University of Connecticut in 2008 under the mentorship of Dr. Jose E. Manautou. Prior to joining Pfizer in 2010, she was a postdoctoral fellow in the laboratory of Dr. Kim Boekelheide at Brown University where she studied the effects of mixed exposures to testicular toxicants. As a member of the Developmental and Reproductive Toxicology group at Pfizer, she is involved in the design and interpretation of both regulatory and investigative DART studies, and the development of in vitro models to assess male reproductive toxicity. She also is actively involved in outreach to local universities. Dr. Campion has been a member of SOT since 2006 and has been very active and engaged in the Society. As a postdoctoral fellow she served as the Chair of the Postdoctoral Assembly, has held offices in the Northeast Regional Chapter and the Reproductive and Developmental Toxicology Specialty Section, and is actively involved in the Mentor Match program.

Goals for SOT: I am excited by the opportunity to serve as a member of the Society of Toxicology’s Awards Committee and to contribute to the recognition of the excellent toxicologists who are members of the Society. As a member of the Awards Committee, one of my goals would be to actively solicit nominations from all levels of membership, from students and postdocs to more senior scientists. I believe that playing an active role in seeking nominations and applications for awards is critical to ensure that a diverse pool of our many talented SOT members are recognized as they so deserve. As a member of SOT Awards Committee I would strive to help the Society achieve this goal and welcome the opportunity to be of service to the Society.

Sarah Campion PhD

Employer: Pfizer Inc.


Schools Attended: University of Connecticut, PhD, Pharmacology and Toxicology, 2008; Gettysburg College, BS, Biology, 2003.

16


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: South Central Regional Chapter 2007–2008; Women in Toxicology Special Interest Group 2012–2014; Reproductive and Developmental Toxicology Specialty Section 2013–present.

Experience: Dr. Camacho is a Senior Staff Fellow at the US Food and Drug Administration’s National Center for Toxicological Research (US FDA/NCTR). Prior to joining NCTR, she worked as a Research Associate at the University of Durham, UK, and as an Academic Visitor at the University of Oxford, UK. Dr. Camacho joined NCTR in 2007, where she has served as principal or co-principal investigator in multiple studies, with a particular focus on the toxicity of endocrine active compounds. Currently, she serves as a scientific coordinator on the CLARITY-BPA (Consortium Linking Academic and Regulatory Insights on BPA Toxicity) program, a research consortium that involves scientists from the US FDA, National Institute of Environmental Health Sciences, National Toxicology Program, and 13 US universities. Dr. Camacho has authored/co-authored 23 peer-reviewed articles in international journals and three book chapters. She is a peer-reviewer for 13 journals in the area of toxicology, including Toxicological Sciences, Archives of Toxicology, and Chemical Research in Toxicology. Dr. Camacho has served as an expert member in several toxicology working groups, including at the US FDA agency level, and as the NCTR representative for the US FDA’s Committee for the Advancement of US FDA Science. She has participated as an expert reviewer in a number of grant and award review committees, both in the US and abroad.

Goals for SOT: Since becoming involved with the Society of Toxicology, back in 2007, I have appreciated its commitment to elevate the quality of the science being conducted in toxicology and related areas. I believe scientific excellence should be at the heart of the SOT mission, to most effectively advance our knowledge in the field of toxicology and ultimately contribute to the promotion of safety and health. If given the opportunity to serve as a member of the SOT’s Awards Committee, I will apply my diverse scientific background to recognize the best science and scientists, and to foster opportunities for trainees and fellows to participate in the various SOT activities. Doing so will ensure the continued positive impact the Awards Committee plays in the recognition and support of the core values of SOT—outstanding science, outreach, education, and training.

Luísa Camacho PhD

Employer: US Food and Drug Administration, National Center for Toxicological Research


Schools Attended: University of Lisbon (Portugal), PhD, Cell Biology, 2003; University of Lisbon (Portugal), BSc, Applied Plant Biology, 1998.

17

Membership Committee candidates continued on next page 4

Membership Committee (Vote for no more than four of eight)

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: FDA Colloquium Organizing Committee 2014; Regional Chapter Collaboration and Communication Liaison 2015–present; South Central Regional Chapter 2002–present, Treasurer 2002–2004, Vice President-Elect 2004–2005 and 2013–2014, Vice President 2005–2006 and 2014–2015, President 2006–2007 and present, Past President 2007–2008; Carcinogenesis Specialty Section 2007–2010; Mechanisms Specialty Section 2003–2005 and 2013–present; Metals Specialty Section 1997–1999; Regulatory and Safety Evaluation Specialty Section 1997; Reproductive and Developmental Toxicology Specialty Section 1990–2010.

Experience: Dr. Ronis' research in alcohol toxicity and nutritional regulation of drug metabolism has been funded by NIH and USDA since 1990. He has trained a large number of undergraduate and graduate students and postdoctoral scholars who have joined SOT and become involved in the organization. He has been involved in leadership positions in the South Central Regional Chapter of SOT since 2002, organizing regional meetings and engaging in student education and training. He has been an active member of many specialty sections. In addition to his activities for SOT, Dr. Ronis is a member of ISSX, AAAS, the Endocrine Society, the American Society for Bone and Mineral Research, the Research Society on Alcoholism, and the American Society of Nutrition (ASN) where he currently serves on the Membership Committee.

Goals for SOT: My goals for SOT are to engage more students and scientists from outside of the immediate field of toxicology to become involved in SOT. For the organization to remain vibrant, we must continue to recruit young people from all branches of academia, industry and government and get them involved from the ground up. We must also continue outreach through the K–12 program to bring additional students into toxicology and into SOT.

Martin J. Ronis PhD

Employer: Lousiana State University Health Sciences Center, New Orleans


Schools Attended: University of Reading, England, PhD, Physiology & Biochemistry, 1985; Cambridge University, England, BS, MA Cantab., Natural Sciences, 1982.

18


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Michigan Regional Chapter 2008; Reproductive and Developmental Toxicology Speciality Section 2009–present, Junior Councilor 2013–2014, Senior Councilor 2014–2015.

Experience: Dr. Rasoulpour is the Toxicology and Risk Assessment Leader for North America and Latin America within the Human Health Assessment (HHA) group of Dow AgroSciences (DAS). His current responsibilities include leadership of mammalian toxicologists and human health risk assessors who provide subject matter expertise for DAS crop protection and seeds platforms. Dr. Rasoulpour also leads several science strategy projects such as incorporation of toxicogenomics into human health safety assessment, representation on discovery assessment teams and development of the new active mammalian toxicity testing paradigm.

Dr. Rasoulpour joined the Dow Chemical Company (Dow) in 2007 as a developmental and reproductive toxicologist in the Toxicology and Environmental Research and Consulting (TERC) laboratories. He assumed the role of Technical Leader in developmental and reproductive toxicology in 2010, subsequently added Technical Leader responsibilities for general toxicology and named as Group Leader of Mammalian Toxicology in 2012. In this role, he served to provide oversight of regulatory testing, investigational research focusing on mode of action and epigenetics, and led a team of DAS molecule focal points charged with scientifically coordinating new active toxicology testing. He transitioned from the Dow laboratory, TERC, to DAS in his current role in 2014. Dr. Rasoulpour’s primary research focus has been in leading the epigenetics research program designed to evaluate potential transgenerational epigenetic phenomena and to determine the adequacy of the current regulatory toxicity testing program to detect such effects. Dr. Rasoulpour has organized numerous symposia and workshops at the Society of Toxicology meetings, and has served as an invited speaker and panelist for scientific sessions at the National Academy of Sciences, ICCA-LRI workshops, ILSI-HESI initiatives, Crop Life America, Society for Toxicologic Pathology, and the Teratology Society. To date, he has authored/coauthored 33 peer-reviewed publications to the scientific literature, as well as authored a book chapter on the topic of male reproductive biology.

Goals for SOT: My goals for SOT with respect to the Membership Committee are aimed at building the toxicologists of the future by combining the strengths of our past in an apical endpoint-driven, but highly impactful and applied science, with the potential of our future in high content, in vitro/in silico technologies and approaches. I will devote my energy within the SOT Membership Committee to provide outreach into closely-related disciplines such as bioinformatics (e.g., machine learning), chemistry (e.g., computational assisted structural activity relationship), and epidemiology and public health, to enhance our robust toxicology membership within academia, government, and industry with individuals who can bring different perspectives to help us grow towards an integrated SOT of the future.

Reza J. Rasoulpour PhD

Employer: Dow AgroSciences


Schools Attended: Brown University, PhD, Pathobiology, 2006; University of Connecticut, BS, Molecular and Cellular Biology, 2000.

19



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Communications Committee 2012–2014, Co-Chair 2012–2013, Chair 2013–2014; Congressional Subcommittee 2013–2014; Rapid Response Task Force 2014–2015; Toxic Substances Control Act Task Force 2014–2015; North Carolina Regional Chapter 2005–2008; Ohio Valley Regional Chapter 2014–present; Southeastern Regional Chapter 2002–2005; Women in Toxicology Special Interest Group 2002–present; Ethical, Legal, and Social Issues Specialty Section 2010–2015; Food Safety Specialty Section 2012–present; Regulatory and Safety Evaluation Specialty Section 2002–2014; Risk Assessment Specialty Section 2005–present.

Experience: Dr. Navarro has practical experience and proven success in creating and sustaining strong relationships within complex organizations. She has a positive track record working with culturally, geographically, and scientifically diverse groups across multiple regions and has served on many commercial trade associations where she has developed credibility in the scientific community through successful issues management. Dr. Navarro believes it is important to support the organizations she is part of through active collaboration. She is energetic, proactive and inspires action by demonstrated involvement. Currently, Dr. Navarro is Head of Givaudan Flavors Product Safety & Regulatory Assurance, North America. She held past roles with other companies both domestically and abroad. In this capacity she had the opportunity to work across global organizations, cross-functionally, and cross-culturally. Dr. Navarro served on the American Board of Toxicology Executive Committee in 2011 and as American Board of Toxicology Exam Chair in 2013.

Goals for SOT: As an elected member to the SOT Membership Committee I would support the direction of the Society leadership to accomplish membership targets which are essential to SOT. I believe that one of the keys to a great society of scientists is recognizing the importance our members bring to the organization and the impact this has on our outward representation to the communities in which we live and work. I would strive to ensure the criteria for membership is relevant for the goals of the Society and that applications for membership are fully validated in this light.

Lisa E. Tonner Navarro PhD, DABT, ERT

Employer: Givaudan Flavors


Schools Attended: University of Florida, Postdoctoral Associate, 1996–1998; Florida Agricultural and Mechanical University, PhD, Toxicology, 1996; Florida State University BS, Biology BA, German, 1990.

20


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Education Subcommittee Undergraduate Educator Network 2010-present; Rapid Response Task Force 2014-2015; South Central Regional Chapter 2001–present, Secretary 2001–2003, Vice President-Elect 2003–2004, Vice President 2004–2005, President 2005–2006, Past President 2006–2007; Women in Toxicology Special Interest Group 1994–present; Specialty Section Collaboration and Communication Group 2012–present; Carcinogenesis Specialty Section 1994–present; In Vitro and Alternative Methods Specialty Section 1994–present, Secretary/Treasurer 2008–2010, Vice President-Elect 2010–2011, Vice President 2011–2012, President 2012–2013, Past President and Councilor 2013–present; Mechanisms Specialty Section 2007–present; Mixtures Specialty Section 2013-present

Experience: Dr. Meyer came to toxicology indirectly after completing degree programs in chemistry, biochemistry, and physiology. Her postdoctoral work at Harvard Medical School and University of North Carolina-Chapel Hill introduced her to pharmacology. She first worked as a toxicologist with her next appointments as research assistant professor at Duke University Medical School and North Carolina State University, where she focused upon chemical carcinogenesis. She currently is a professor of toxicology at the University of Louisiana-Monroe School of Pharmacy where she has taught for 16 years. Her teaching responsibilities include graduate education and instruction in drug safety to professional PharmD students and in the undergraduate (BS, Toxicology) program. She is a Fellow of the Academy of Toxicological Sciences. She has been funded by the Department of Defense for hazard identification of munitions chemicals and their environmental degradation products. More recently, she is conducting USDA-funded research for drug development from medicinally important herbal supplements. Dr. Meyer has mentored 13 graduate students and published 55 peer-reviewed publications and 2 chapters in graduate toxicology textbooks. She has reviewed grants for NIH and CDMRP, served on federal scientific advisory committees (NTP/NIEHS and CFSAN/FDA) and conducted external peer reviews for EPA and ATSDR. Dr. Meyer has served on the editorial board of Toxicological Letters and is currently serving for Journal of Applied Toxicology and Journal of Biochemical and Molecular Toxicology.

Goals for SOT: I strive to see SOT secure a reputation as a highly respected, trusted voice for the science of toxicology and to be a leading player among the professions endeavoring to better public and environmental health. I believe SOT should play a prominent role towards minimizing chemical toxicity through promotion of new knowledge resulting from members’ research, provision of a platform for debate of rational, science-based approach to regulation, support of training and mentoring of future toxicologists, and presentation of a balanced message to the public. Through my role on the Membership Committee, I would work to identify and recruit members with diverse backgrounds and perspectives with the energy and commitment to advance the profession of toxicology through active engagement with the Society.

Sharon A. Meyer PhD

Employer: University of Louisiana Monroe


Schools Attended: Cornell University, PhD, Physiology, 1984; Iowa State University, MS, Biochemistry, 1977; Iowa State University, BS, Chemistry, 1971.

21



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Continuing Education Committee 2006–2008, Chair 2007–2008; Education Committee Ad Hoc Member 2013–2015; Global Strategy Focus Group Co-Chair 2008–2010; Global Strategy Task Force 2009–2012; Mid-Atlantic Regional Chapter 2002–2005; Midwest Regional Chapter 2011–present; American Association of Chinese in Toxicology Special Interest Group 2006–present; Regulatory and Safety Evaluation Specialty Section 2000–present; Reproductive and Developmental Toxicology Specialty Section 2000–present.

Experience: Dr. Hew is a Scientific Director at the Global Drug Safety Research and Evaluation Department of Takeda Pharmaceutical Company in Deerfield, Illinois. His current responsibilities include providing scientific and strategic leadership for the nonclinical development of new drug candidates, writing the nonclinical summaries of regulatory documents and managing toxicological issues associated with these candidates. He received his PhD in Anatomy and Cell Biology from the University of Michigan, Ann Arbor. Following graduation, he worked as a study director in reproductive toxicology at Ciba-Geigy Corporation and Novartis Pharmaceuticals Corporation. He also served as the Manager of Reproductive Toxicology at Springborn Laboratories; Associate Director in the Nonclinical Drug Safety Evaluation Department of Purdue Pharma; and Director of Toxicology in Emisphere Technologies, Inc. He has more than 20 years of experience in drug safety assessment, with special interests in reproductive toxicology and juvenile animal toxicity studies. In addition to authoring numerous toxicology reports and regulatory documents, he is the lead or co-author of a number of peer reviewed journal articles and book chapters. Dr. Hew was a member of the editorial board in the Reproductive Toxicology journal, and is currently a member of the editorial board of the International Journal of Toxicology as well as the Journal of Toxicological Sciences. Since 2010, he has been the course director and a speaker of the annual week-long course Toxicology for Industrial and Regulatory Scientists, sponsored by the American College of Toxicology (ACT). In addition to SOT, he also is a member of ACT, Teratology Society, Japanese Teratology Society, Middle Atlantic Reproduction and Teratology Association (MARTA), and ILSI/HESI Developmental and Reproductive Toxicology Technical Committee. He is a past president of MARTA. In SOT and Teratology Society, he has served on various committees, including the Chair of the Continuing Education Committee in both societies.

Goals for SOT: The Membership Committee is an important committee in SOT because the quality and constitution of its members will determine and influence the future of the Society. If elected, I will work with members of the committee to accomplish the goals of the Society’s strategic plan as well as encouraging participation from young scientists and scientists from outside of North America.

Kok Wah Hew PhD, DABT

Employer: Takeda Pharmaceutical Company


Schools Attended: University of Michigan, PhD, Anatomy and Cell Biology, 1993.

22


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Mentoring Breakfast Planners 2013–2014; Women in Toxicology Mentoring Initiative 2012–2013, Women in Toxicology Awards Committee 2014–2015; Mid-Atlantic Regional Chapter 2005–present; Northern California Regional Chapter 2002–2005; Special Interest Group Collaboration and Communication Group 2010–2014, Co-Chair 2010–2013, Chair 2013–2014; Women in Toxicology Special Interest Group 2001–present, Secretary/Treasurer 2002–2004, Councilor 2007–2009, Vice President 2010–2011, President-Elect 2011–2012, President 2012–2013, Past President 2013–2014; Neurotoxicology Specialty Section 2000–2009; Regulatory and Safety Evaluation Specialty Section 2006–present; Reproductive and Developmental Toxicology Specialty Section 1998–2001.

Experience: Dr. Chadwick received her PhD in Pharmacology and Toxicology from Duke University with a dissertation on neurodevelopmental toxicity of a pesticide, chlorpyrifos. She continued research with pesticides at the University of Washington in Seattle. Dr. Chadwick joined the Pharmaceutical Industry at Targeted Genetics in 2001 and then Roche Palo Alto and is currently an Associate Director and Therapy Area Head for Fibrotic and Metabolic Diseases in Drug Safety Evaluation at Bristol-Myers Squibb. In her current capacity she is involved with therapeutics at all stages of development, discovery through life-cycle management. Dr. Chadwick is a Full member of the Society of Toxicology, American College of Toxicology, and is a Diplomate of the American Board of Toxicology. She has been a very active member of the Women in Toxicology Special Interest Group of the SOT and served as Co-Chair of SOT’s Special Interest Group Collaboration Group.

Goals for SOT: Through my involvement in the Special Interest Group Collaboration Group we sought to expand the reach of the SOT by creating opportunities for international students to interact with members of the Society and access resources (to a limited extent) without having to become SOT members, which is cost-prohibitive in many regions of the world. Such opportunities expanded the reach of SOT and will hopefully encourage students to pursue the field of toxicology. Through the Membership Committee, I would like to continue and expand on such efforts by diversifying our membership and to build the next generation of toxicologists by facilitating exposure to and participation in SOT.

Kristina D. Chadwick PhD, DABT

Employer: Bristol-Myers Squibb


Schools Attended: Duke University, PhD, Pharmacology & Toxicology, 2000; Mount St. Mary’s University, BS, Biochemistry, 1996.

23



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Specialty Section Collaboration and Communication Group 2012–2014; Regulatory and Safety Evaluation Specialty Section 2009–present, Vice President-Elect 2010–2011, Vice President 2011–2012, President 2012–2013, Past President 2013–2014.

Experience: Dr. Brown is an Associate Director for Pharmacology and Toxicology in the Center for Drug Evaluation and Research at the US FDA. He has been at the US FDA since 1996 when he joined the Division of Dermatology and Dental Drug Products as a Pharmacology/Toxicology reviewer. He was supervisor for Pharmacology/Toxicology in this Division from 2003–2008. Prior to coming to the US FDA he was a Pharmacology Research and Training Fellow in the National Cancer Institute from 1991–1996. He received his PhD in Toxicology from the University of Maryland in 1991. Dr. Brown is involved in policy and guidance development in a number of areas for the pharmacology and toxicology discipline within CDER.

Goals for SOT: As a member of the Membership Committee I would seek to maintain the standards set by the Society for new members while also assuring qualified candidates are not excluded.

Paul Brown PhD

Employer: US FDA


Schools Attended: University of Maryland, PhD, Toxicology, 1991; Pennsylvania State University, BS, Biology, 1985.

24


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Communications Subcommittee: Wordwide Web Task Force 2008–2010; Allegheny-Erie Regional Chapter 2005–2010; Ohio Valley Regional Chapter 2002–2005; Immunotoxicology Specialty Section 2005–present, Postdoctoral Representative 2007–2010.

Experience: Dr. Anderson is a Research Biologist at the National Institute of Occupational Safety and Health in Morgantown, West Virginia. As a member of the Allergy and Clinical Immunology Branch in the Health Effects and Laboratory Division, Dr. Anderson serves as the Team Leader for the Hazard Identification and Immunotoxicology Team. Her main focus during the last eleven years has been understanding how exposure to chemicals, particularly antimicrobial and disinfectants, contribute to allergic disease. Early in her career she recognized how certain chemicals can indirectly influence allergic disease and therefore not be identified by traditional screening methods. Her recent efforts have been focused on further characterizing these types of chemicals by identifying their mechanisms of action related to allergy and asthma. This research has helped to identify novel mediators of allergic disease such as the innate immune system, additional T-cell pathways, the microbiome, and regulatory RNAs. Dr. Anderson is also an Assistant Adjunct Professor in the Immunology and Microbial Pathogenesis program at West Virginia University. Her research related to immunotoxicology has resulted in author/co-authorship of more than 40 peer-reviewed publications and a book chapter.

Goals for SOT: I have been a member of SOT since my postdoctoral years and during this time, I have learned the importance of membership for career development. SOT provides its members many opportunities to advance their knowledge of toxicology through attendance at the Annual Meeting and by networking with other toxicologists. In addition, I feel that toxicology is a very important and growing field and it is critical that we recruit the individuals who can provide us with the expertise so we can continue to thrive as scientific leaders while contributing significantly to the health related issues. My goal for SOT is to recruit new membership while encouraging existing members to become more actively involved so we can continue to be recognized as an outstanding society. I look forward to serving on the Membership Committee and the opportunity to have a more active role in SOT.

Stacey E. Anderson PhD

Employer: CDC/NIOSH


Schools Attended: West Virginia University, PhD, Cellular and Molecular Biology, 2004; West Virginia University, BA, Biology, 1998.

25

Nominating Committee—From the Membership-at-Large candidates continued on next page 4

Nominating Committee—From the Membership-at-Large (Vote for one of three)

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Animals in Research Committee, Ad Hoc Member 1998–1999; Celebrating Membership Accomplishments Task Force 2012–2014; Dermal Toxicology Specialty Section 1992–present, Vice President-Elect 2001–2002; Vice President 2002–2003; President 2003–2004; Past President 2004–2005; Immunotoxicology Specialty Section 1992–present, Councilor 1993–1994; Distinguished Toxicology Scholar Award 2015; Enhancement of Animal Welfare Award 2003; Neurotoxicology Specialty Section Best Abstract Award 2006; Vos Award—Career Achievement in Immunotoxicology 2005.

Experience: Professor Kimber holds, or has held, a variety of positions on national and international expert and scientific advisory committees. Currently these include: Member UK Medicines and Healthcare products Regulatory Agency (MHRA), Devices Expert Advisory Committee, Program Advisor Food Standards Agency Food Allergy and Intolerance Program, Member Scientific Advisory Board National Institute for Biological Standards and Control, and Member Medical Research Council Translational Research Group. Professor Kimber was Chair of the Board of the UK National Center for the Replacement, Refinement and Reduction of Animals in Research (2008–2013), and was President of the British Toxicology Society (2012–2014). Professor Kimber has won a number of awards and prizes, including the Eurotox Bo Holmstedt Memorial Fellowship Award and Lecture (2010), and the British Toxicology Society Barnes Prize (2015). In 2011, Professor Kimber was awarded an OBE in the Queen’s Birthday Honors list for services to science.

Goals for SOT: My aim is to support and promote the interests of SOT, through the Nominating Committee, by the identification of outstanding candidates for positions within, or recognition by, the Society.

Ian Kimber OBE, PhD, ATS

Employer: University of Manchester, UK


Schools Attended: University of Manchester, PhD, Immunology, 1981, MSc, Immunology, 1978, BSc, Biology, 1971.

26


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Rapid Response Task Force 2014–2015; Carcinogenesis Specialty Section 2000–2001; Mechanisms Specialty Section 1994–present.

Experience: Dr. Dietrich is Head of the Human and Environmental Toxicology Unit at the University of Konstanz, Germany. He is currently a Fellow of the Academy of Toxicological Sciences (ATS), and a EUROTOX-Registered Toxicologist (ERT). He served as a consultational toxicologist and expert panelist for SwissMedic (Registration Authority for Pharmaceuticals in Switzerland), the US EPA, WHO, OECD and the EC and as an adjunct judge, recourse commission, Swiss high court of administration/court of mediation and appellation, Bern, Switzerland. He chaired the Endocrine Disruption Task Force (ED-TF) at the Institute of Consumer Health and Safety, ECVAM, JRC, Ispra, Italy “In Vitro Technologies for the Detection of Endocrine Effects” from 2003–2009, as well as co-chaired the EDTA-VMG non-animal of the OECD, Paris, France, together with Steven Bradbury of the US EPA from 2007–2010, is a member of the Presidential Task Force on Marine and Freshwater Toxins of the AOAC since 2003, and member of the Board of Directors for CAAT-EU (Center for Alternatives to Animal Testing) since 2010. Dr. Dietrich is currently one of the elected external experts in the area “Life Sciences for Human Well-Being” advising the European Parliament (2014–present). Since 2010 he co-leads an advanced course program for the Safety Sciences of the Medicines, a pan-European course program encompassing 20 intensive courses co-financed by big-pharma and the European Community, which leads to a Master of Safety Sciences of the Medicines. He has more than 30 years experience working in the forefront of international research, risk assessment and regulatory toxicology, published more than 150 peer-reviewed articles in international journals, severed as board member on a number of toxicology journals, as Editor Asia and Asia-Pacific (2004–2012) for Toxicology In Vitro and as Editor-in-Chief for Chemico-Biological Interactions since 2012. Dr. Dietrich is widely recognized for his expertise in endocrine disruption research, natural toxins and environmental and human risk assessment, also including natural products e.g. cyanotoxins, mycotoxins and plant toxins.

Goals for SOT: Since participating at SOT’s Annuals Meetings as a postdoc in Jim Swenberg’s lab and joining SOT in 1994, I have been inspired by the high motivation, great dedication, work ethics, and integrity displayed by the key representatives of SOT that I have had the opportunity to meet during the past decades. The field of toxicology has dramatically changed during the past decades, becoming more complex and broader a field and with seemingly greater demands from the wider public. The latter not only requires continuous adaptation of teaching and research areas, but also a stronger effort at making the Society of Toxicology be recognized as a learned society that will and can voice an opinion of expertise to situations and areas of public concern involving public and environmental health. It is one of my goals to draw on the breadth and depth of knowledge represented by the membership of SOT to aid and support decision processes of our governments in the quest to provide better human and environmental protection. The Society of Toxicology with its mix of academics, industrial, and governmental scientist as well as scientists working for NGOs, has the unique capability to develop well-researched and balanced opinions that will advance our Society. I see it as a responsibility of SOT to make use of these unique capabilities and thus to embark on a more proactive course in upholding excellence in toxicological sciences.

Daniel R. Dietrich PhD, ATS

Employer: University of Konstanz, BW, Germany


Schools Attended: ETH Zurich, Switzerland, Habilitation (Venia legendi) in Toxicology, 1995; UNC Chapel Hill, Postdoctoral Fellow with Prof. James Swenberg, 1989–1991; ETH Zurich, Switzerland, PhD, 1988; ETH Zurich, Switzerland, MSc Toxicology/Limnology, 1984; University of Zurich, Switzerland, BSc, Biology, 1982.

27

Nominating Committee—From the Membership-at-Large candidates continued on next page 4


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Global Collaboration and Initiatives 2014–present; Dermal Toxicology Specialty Section 2007–2014; Immunotoxicology Specialty Section 2000–present; AstraZeneca Traveling Lectureship Award 2010; Board of Publications Award 1995; Immunotoxicology Specialty Section Outstanding Young Investigator Award 2008.

Experience: Dr. Corsini is Associate Professor in Toxicology at the School of Pharmacy at the University degli Studi di Milano, Milan, Italy. She is active in training undergraduate and graduate students and in research. Her research focuses on the refinement of alternative in vitro tests for immunotoxicity, and on the understanding at the molecular level the mechanism of action of immunotoxic/immunomodulatory compounds (i.e. perfluorinated compounds, pesticides, vegetal extracts, drugs) on innate and adaptive immunity. She has authored more than 140 research publications in the area of toxicology. She is active in numerous scientific and professional organizations, serves on several editorial boards of toxicology and in vitro journals. From 1999–2005 she served as Treasurer of the Association for in vitro Toxicology; from 2009–2013 she was a member of the EUROTOX Education Subcommittee, from 2005–2011 she was the Chair of the Immunotoxicology and Chemical Specialty Section at EUROTOX; from 2010 she was a member of the IUTOX Executive Committee and from 2013 she also was a member of the EUROTOX Executive Committee.

Goals for SOT: Being a professor at the University, one of the things I do is to foster toxicology, both scientifically and educationally; within the SOT I would like to help to create a network to enhance and harmonize toxicological education, awareness of emerging toxicological challenges, and to promote career development of young toxicologists.

Emanuela Corsini PhD

Employer: University of Milan, Italy


Schools Attended: University degli Studi di Milano, Italy, PhD, Food and Environmental Toxicology, 1993; University degli Studi di Milano, Italy, MS, Food Sciences, 1987.

28

Nominating Committee—From Regional Chapters (Vote for one of five)

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Northeast Regional Chapter 2003–2004 and 2010–present. Councilor 2014–2015, Vice President 2015–present; Carcinogenesis Specialty Section 1996–2006; Drug Discovery Toxicology 2007–present; Regulatory and Safety Evaluation 2007–present.

Experience: Dr. Papanikolaou is a Senior Principal Scientist in Drug Safety Research and Development at Pfizer Inc. In his role, he is responsible for the preclinical safety assessment of new therapeutic agents and preparation of related regulatory documents.

Dr. Papanikolaou received his doctorate in Pharmaceutical Sciences (Toxicology Program) from the University of Connecticut in 1999 and was a Susan G. Komen Breast Cancer Foundation Postdoctoral Fellow at the University of Connecticut Health Center, School of Medicine, from 1999–2006, where he carried out research on the molecular pathogenesis of breast cancer. He is author/co-author of multiple publications, including peer-reviewed and review articles, on the topic of carcinogenesis. Dr. Papanikolaou has been a member of SOT since 1996. He is currently the Vice President of NESOT and was a Councilor from 2012–2014. He also has served as the Pfizer company liaison to Pfizer SOT Undergraduate Student Travel Award recipients.

Goals for SOT: My goal as a member of the Nominating Committee is to help identify a slate of vibrant and diverse candidates who in their leadership roles will continue to expand the field of toxicology and advance the Society’s guiding principles.

Alexandros Papanikolaou PhD, DABTNortheast Regional Chapter



Schools Attended: University of Connecticut School of Medicine, Postdoctoral Fellow, 1999–2006; University of Connecticut, PhD, Pharmaceutical Sciences (Toxicology Program), 1999; University of Connecticut, BS, Psychology, 1992.

29

Nominating Committee—Regional Chapters candidates continued on next page 4


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Neurotoxicology Specialty Section Best Abstract Award 2006; Northern California Regional Chapter 2008–present, Vice President-Elect 2013–2014, President 2014–2015, Past President and Councilor 2015–present; Pacific Northwest Regional Chapter 2002–2008, Vice President-Elect 2008–2009; Women in Toxicology Special Interest Group 2006–present; Neurotoxicology Specialty Section 2000–present, Councilor 2005–2007, Vice President-Elect 2010–2011, Vice President 2011–2012, President 2012–2013, Past President and Councilor 2013–2014.

Experience: Dr. Lein is currently Professor of Neurotoxicology at the University of California-Davis (UC Davis). She earned a MS in Environmental Health (1983) from East Tennessee State University, a PhD in Pharmacology and Toxicology (1990) from the University at Buffalo School Of Medicine, and completed a postdoctoral fellowship in molecular immunology at the Roswell Park Cancer Institute in Buffalo, New York. Following her postdoctoral training, Dr. Lein worked in the private sector as an environmental health analyst at a nuclear fuel reprocessing facility in western New York State prior to joining the faculty of the Biology Department at Canisius College, a primarily undergraduate institute in Buffalo, New York. In 1999, she accepted a faculty position in the Division of Toxicological Sciences in the Department of Environmental Health Sciences at the Johns Hopkins Bloomberg School of Public Health. In 2003, Dr. Lein was recruited to the Center for Research on Occupational and Environmental Toxicology (CROET) at Oregon Health & Science University, and in 2008, she was recruited to UC Davis. She currently serves as Vice-Chair of the Department of Molecular Biosciences, Chair of the UC Davis graduate group in Pharmacology and Toxicology, Director of the NIEHS-funded training program in Environmental Health Sciences and Director of the UC Davis NINDS CounterACT Center of Excellence. Dr. Lein’s research focuses on cellular and molecular mechanisms of neurotoxicity with particular emphasis on mechanisms by which organophosphorus pesticides and persistent organic pollutants interfere with neuronal connectivity and contribute to childhood diseases such as autism and asthma. She also is interested in the development of alternative models for developmental neurotoxicity testing (DNT) and is a member of the steering committee for TestSmart: DNT, a collaborative program between US and European scientific agencies that is focused on developing alternative models for developmental neurotoxicity testing. Her teaching responsibilities include both veterinary and graduate courses in neurochemistry, developmental neurobiology, neurotoxicology and autonomic pharmacology. Dr. Lein serves as an Associate Editor for the journals Toxicology and Applied Pharmacology, Neurotoxicology and Teratology, and NeuroToxicology, and as a member of the editorial board for Toxicological Sciences.

Goals for SOT: My goals for SOT are to ensure diversity within the leadership of SOT. This includes diversity with respect to not only race, gender, and cultural background, but also professional experience, including disciplinary expertise and employment sector (academia, industry, government). I also seek to identify nominees for key leadership positions in SOT who are committed to education of the next generation of scientists in toxicology and to encouraging the engagement of toxicologists in dialog with politicians, policy makers, and the lay public.

Pamela J. Lein MSEH, PhDNorthern California Regional Chapter

Employer: University of California Davis


Schools Attended: University at Buffalo, PhD, Pharmacology and Toxicology, 1990; East Tennessee State University, MS, Environmental Health, 1983; Cornell University, BS, Biology, 1981.

30


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Pacific Northwest Regional Chapter 2002–2005; Southern California Regional Chapter 2006–present, Councilor 2008–2012, Vice President-Elect 2012–2013, Vice President 2013–2014, President 2014–2015, Past President and Councilor 2015–present; Drug Discovery Toxicology Specialty Section 2013–2014; Immunotoxicology Specialty Section 2002–2012; Neurotoxicology Specialty Section 2014–present; Regulatory and Safety Evaluation Specialty Section 2002–present; Toxicologic and Exploratory Pathology Specialty Section 2014–present.

Experience: Dr. Jabbour is currently the Director of Toxicology at Neurocrine Biosciences. He has 20 years of experience in scientific research including 14 years of experience in pharmaceutical research (both CRO and pharmaceutical industry). Dr. Jabbour received his MS and PhD in Environmental Sciences with a concentration in Toxicology from The University of Texas (Houston) in 1991 and 1994, respectively. In the years between 1994 to 2000, Dr. Jabbour worked at The University of Washington (Seattle) in the positions of postdoctoral research fellow and scientist conducting research investigations of ozone and beryllium toxicity. In the next 4 years, Dr. Jabbour worked at a Contract Research Organization (SNBL USA) as an immunotoxicologist/study director conducting studies in non-human primates. Since 2005, Dr. Jabbour worked in the pharmaceutical industry across the whole process from IND to NDA approval of drugs for several clinical indications such as CNS, endocrinology, cardiovascular, antimicrobials, inflammation, and oncology. Dr. Jabbour has authored several scientific publications and regulatory documents. He is certified in general toxicology, becoming a Diplomate of the American Board of Toxicology in 2003. Dr. Jabbour has been a member of SOT since 2002 and he served in several positions (Councilor, Vice President, President) in the SOT Southern California Regional Chapter.

Goals for SOT: My goals are in alignment with the SOT’s mission of advancing the science and knowledge of toxicology among SOT members and the scientific community at large. Due to the diverse scientific nature of toxicology dealing with complex interdisciplinary issues, it is prudent to highlight the importance of working with scientists from other disciplines in order to expand the scientific background of our field and to utilize cutting edge information and technologies. Also, one of my priorities remains outreach activities to local high schools and local colleges to encourage students to consider careers in toxicology. I also strongly believe that toxicologists have an important role in their local communities to disseminate the message of toxicology to the public and also to act as a resource of subject matter experts working with others to solve pertinent regional public health issues. Finally, integral to excellence in our field is to continually work toward the SOT’s mission of identifying and acknowledging achievements among our members.

Jacob Jabbour PhD, DABTSouthern California Regional Chapter

Employer: Neurocrine Biosciences


Schools Attended: University of Washington, Postdoctoral Fellow, Toxicology, 1997; University of Texas, PhD, Toxicology, 1994.

31

Nominating Committee—Regional Chapters candidates continued on next page 4


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Research Funding Committee 2012–2014; Student Advisory Council: Specialty Section Graduate Committee 2005–2006; North Carolina Regional Chapter 2002–present, Councilor 2009–2011, Vice President-Elect 2011–2012, Vice President 2012–2013, President 2013–2014, Past President and Councilor 2014–2015; Women in Toxicology Special Interest Group 2006–present; Immunotoxicology Specialty Section 2005–present, Student Representative 2005–2006, Postdoctoral Representative 2006–2007, Junior Councilor 2013–2014, Senior Councilor 2014–2015; Reproductive and Developmental Toxicology Specialty Section 2009–2012; Outstanding Young Immunotoxicologist Award 2013.

Experience: Dr. DeWitt is an Associate Professor in Pharmacology & Toxicology at the Brody School of Medicine at East Carolina University. She investigates how immunopathogenesis induced by exposure to environmental chemicals alters neurological development and uses models of both autism spectrum disorder and Alzheimer’s disease to understand these relationships. She has been an active SOT member since her postdoctoral fellowship, at both the regional level and at the national level. She was a Postdoctoral Representative to the Immunotoxicology Specialty Section and remained active in the specialty section by serving on various subcommittees and as a Councilor. She served on the SOT Research Funding Committee and headed the North Carolina Regional Chapter 2013–2014. She serves on the editorial boards of the Journal of Immunotoxicology and the Journal of Toxicology and Environmental Health Part A. She has reviewed grant proposals for the CDMRP and CDC, served as a consultant for the National Toxicology Program and the Dutch government, and was on the mechanisms working group for Monograph 110 of the International Agency for Research on Cancer. She also is an active member of the Society of Environmental Toxicology and Chemistry and recently published her first edited book.

Goals for SOT: My professional development has been intimately tied with my involvement in SOT and from the support of SOT members and activities. Through SOT, I have become a better mentor, colleague, communicator, and scientist. Through SOT, I have become better informed about the larger issues in toxicology related to scientific funding, animal welfare, and governmental regulation and oversight. Serving on the Nominating Committee would allow me to help identify members who share my desire to serve SOT and to ensure that new and current SOT members receive the same benefits that I have had as a member of SOT.

Jamie C. DeWitt BS, PhDNorth Carolina Regional Chapter

Employer: East Carolina University


Schools Attended: Indiana University-Bloomington, PhD, Environmental Science and Neural Science, 2004; Michigan State University, BS, Environmental Science and Biology, 1992.

32


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Endowment Fund Board 2012–2015; Mid-Atlantic Regional Chapter 2014–present, Vice President-Elect 2015–present; North Carolina Regional Chapter 2001–2002; Northeast Regional Chapter 2011–2014; Drug Discovery Toxicology Specialty Section 2013–present; Regulatory and Safety Evaluation Specialty Section 2002 and 2013–present; Reproductive and Developmental Toxicology Specialty Section 2000–2004; Toxicologic and Exploratory Pathology Specialty Section 1999–present, Councilor 2008–2010, Vice President-Elect 2010–2011, Vice President 2011–2012, President 2012–2013, Past President 2013–2014.

Experience: Dr. Barlow became the Global Head of Toxicology, Pathology and Laboratory Animal Medicine at Johnson & Johnson in 2014. He has responsibilities for these three functions, as well as mechanistic and investigative toxicology, and safety pharmacology, at two sites in the US and one site in Europe. Prior to joining Johnson & Johnson, Dr. Barlow spent eleven years in various roles at Sanofi. From bench pathologist to toxicology project team member and ultimately various leadership roles, he has gained diverse experiences in pharmaceutical research and development during his career. Dr. Barlow joined SOT early in his graduate program and has taken an active role in specialty section as well as regional chapter leadership, and recently completed his tenure on the SOT Endowment Fund Board. Other toxicology and pathology experiences outside of his pharmaceutical roles include several technical report peer review panels for the National Toxicology Program (NTP) and he is currently a member of the Board of Scientific Councilors for the NTP.

Goals for SOT: It is imperative we identify individuals with outstanding scientific abilities and strong leadership qualities to guide the SOT to a successful future. My goal for the Nominating Committee is to engage with scientists across various disciplines in toxicology to help ensure that we identify diverse and energetic individuals willing to serve the SOT and provide leadership for the organization.

Norman J. Barlow DVM, PhD, MBA, MLDMid-Atlantic Regional Chapter

Employer: Johnson & Johnson


Schools Attended: Penn State University, MBA and MLD, Business Management and Leadership Development, 2009; North Carolina State University/CIIT, PhD, Comparative Biomedical Sciences (Toxicology), 2003; Michigan State University, DVM, 1996; Kalamazoo College, BA, Biology, 1992.

33

Nominating Committee—Specialty Sections candidates continued on next page 4

Nominating Committee—From Specialty Sections (Vote for two of nine )

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Scientific Liaison Coalition–Epigenetics Committee 2011; Postdoctoral Assembly 2006–2010; North Carolina Regional Chapter 2006–present, Councilor 2011–2013, Vice President-Elect 2015–present; Carcinogenesis Specialty Section 2009–present; Metals Specialty Section 2006–present, Postdoctoral Representative 2008–2010, Councilor 2012–2014; Stem Cells Specialty Section 2010–present, Interim Officer 2010–2011, Secretary/Treasurer 2011–2014, Vice President-Elect 2014–2015, Vice President 2015–present; Metals Specialty Section Postdoctoral Award 2009; North Carolina President’s Award for Research Competition (PARC) 2007, 2008, 2009, and honorable mention 2006.

Experience: Dr. Tokar is currently Group Leader of the Stem Cell Toxicology Group in the National Toxicology Program Laboratory (NTPL) at NIEHS. He received his PhD in Cancer Biology from Michigan State University and completed a postdoctoral fellowship at the National Cancer Institute at NIEHS (mentor Dr. Michael Waalkes), where he studied the role of stem cells in inorganic carcinogenesis, particularly with arsenic and cadmium. As head of the Stem Cell Toxicology Group, he investigates the involvement of stem cells in the pathogenesis of diseases associated with exposure to NTP-relevant chemicals, with a focus on carcinogens. He has trained numerous students and fellows, served on several postdoctoral science advisory and doctoral supervisory committees, and served as an expert scientific reviewer on toxicology-related funding applications and risk assessment documents. He has nearly 60 publications, serves on the editorial review boards for Environmental Health Perspectives and Toxicology and Applied Pharmacology, and is an active reviewer for several journals including Carcinogenesis, Stem Cells, Toxicological Sciences, Archives of Toxicology, and Chemical Research in Toxicology. Since joining in 2006, Dr. Tokar has been actively involved in the SOT: he received the Metals Specialty Section (SS) Postdoctoral Research Award (2009) and has served the Metals SS as Postdoctoral Representative and Councilor. He also holds/held positions in the Stem Cells SS (co-founder; Secretary/Treasurer; current Vice President) and the North Carolina Regional Chapter (Councilor; current Vice President-Elect). He has chaired and/or presented at several SOT Annual Meeting sessions including symposia on “The Fetal Basis of Adult Disease” (2010) and “Patient-Specific Stem Cells as Models for Gene, Drug, and Environment Interactions in Disease” (2016), and continuing education courses on “Stem Cells in Toxicology” (2012, 2014) and “Toxic Effects of Metals” (2013).

Goals for SOT: To maintain and enhance the path of excellence and success of the Society, we must elect the strongest candidates while being inclusive of all groups and communities represented by the membership. I will work closely with the other Nominating Committee members to secure nominations of the most highly-qualified and creative candidates and ensure a ballot that best represents the diversity of the SOT membership. This approach, I feel, will guarantee officers and committee members that will continue to promote advancements in toxicology, help the Society achieve an even higher profile as an authority and resource on public and environmental health, and best ensure the SOT reaches its objectives and broadens its global impact on toxicology as well as other scientific disciplines. Serving on the Nominating Committee is particularly appealing to me because of the diverse processes of the Society that the committee impacts. I welcome the opportunity to serve on this Committee and will always actively work to help build and strengthen the Society. I am excited for the opportunity to contribute to the SOT and to work with colleagues that are as passionate and committed to the Society as I am.

Erik J. Tokar PhDStem Cells Specialty Section

Employer: NTP, NIEHS


Schools Attended: Michigan State University, PhD, Zoology and Medicine (Cancer Biology), 2005; University of Michigan, BS, Biology, 1997.

34


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Central States Regional Chapter, Councilor 2009–2011; Gulf Coast Regional Chapter 2005; Lone Star Regional Chapter 2006–2008, Secretary 2006–2007, Vice President-Elect 2007–2008; South Central Regional Chapter 2002; Association of Scientists of Indian Origin Special Interest Group; 2007–present; Toxicologic and Exploratory Pathology Specialty Section 2007–present, Vice President-Elect 2014–2015, Vice President 2015–present; Board of Publications Award 1999.

Experience: Following his doctoral and residency training, Dr. Ramaiah accepted a tenure track faculty position in the department of Veterinary Pathobiology, College of Veterinary Medicine at Texas A&M University. During his ~6 year stint as a faculty at Texas A&M, Department of Pathobiology and Interdisciplinary Faculty of Toxicology, He pursued his independent research on an NIH-NIAAA funded research grant on alcoholic hepatitis and non alcoholic fatty liver syndrome. In addition to his research, Shashi participated in diagnostic clinical pathology service, residency training and graduate student teaching at Texas A&M University. Since 2008, Dr. Ramaiah has been employed by Pfizer, overseeing translational biomarker strategies for developing innovative medicines.

Dr. Ramaiah has served on the editorial boards of Toxicologic Pathology, International Journal of Toxicology and American Society of Veterinary Clinical Pathology. He also has served on the Outreach Committee and has chaired the International Subcommittee of the Continuing Education Committee of Society of Toxicologic Pathology. Dr. Ramaiah has published in the areas of toxicology, clinical pathology and biomarkers and has served as mentor for an ACVP-STP Coalition fellow. He is actively involved in training students of clinical pathology and toxicology as an adjunct faculty member at Texas A&M University.

Goals for SOT: It is an honor to be nominated to run for the Nominating Committee of SOT and to represent the Toxicology and Exploratory Pathology Specialty Section. If elected, I would be thrilled to have the opportunity to contribute to the vision of SOT to be an international leader for improving human, animal, and environmental health. If elected, I will work diligently to accomplish the education, outreach, and diversity strategic goals of the Society. I will diligently strive to broaden the scope and practice of toxicology by fostering integration of toxicology with discipline such as exploratory pathology, translation, and biomarker approaches. I will work to ensure the continued success of current and future members by supporting mentoring of students both locally and at the international level. I will continue to forge stronger collaboration with other toxicology and pathology societies to educate the public and advance scientific progress in toxicology and human health.

Shashi K. Ramaiah DVM, PhD, DACVP, DABTToxicologic and Exploratory Pathology Specialty Section



Schools Attended: University of Florida, DACVP, Residency in Pathology, 2002; University of Louisiana, PhD, Toxicology, 1999; University of Agricultural Sciences, BVSc, MVSc, 1992 and 1995.

35



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Midwest Regional Chapter 2015–present, Program Committee 2015; Women in Toxicology Special Interest Group 2014–2015; Clinical and Translational Toxicology Specialty Section 2015–present; Drug Discovery Toxicology Specialty Section 2014–2015; Immunotoxicology Specialty Section 2012–2014; Molecular and Systems Biology Specialty Section 2012–present; Regulatory and Safety Evaluation Section 2014–present.

Experience: Dr. O’Lone received BAs in Biology and German from Drew University, and earned an MA and PhD in Molecular Biology, Cell Biology, and Biochemistry from Boston University. While completing her PhD, she also worked on secondary science education as a National Science Foundation GK-12 Fellow. Dr. O’Lone currently works at the Health and Environmental Sciences Institute, managing programs on genomics and biomarkers of nephrotoxicity. Previously, her work at HESI has spanned immunotoxicology, biomonitoring, and other scientific initiatives. Prior to joining HESI, Dr. O’Lone worked as a Program Manager at the Brigham and Women’s Hospital Biomedical Research Institute, working with research centers and programs spanning cardiovascular and metabolic diseases, musculoskeletal research, cancer research, imaging, and regenerative medicine.

Dr. O’Lone has co-authored several book chapters and scientific publications. She is a Full member of the Society of Toxicology, and in 2015 she has worked with the SOT Midwest Regional Chapter Program Committee. She has served as a member of the steering team of the Federation of Clinical Immunology Societies (2012–2014).

Goals for SOT: As a member of the Nominating Committee, I would work to identify strong, innovative, and diverse leadership for SOT to enhance the organization’s efforts to build bridges across scientific disciplines, explore novel opportunities and partnerships, and support scientific advances. Strengthening such connections will contribute toward promoting education in toxicology, fostering international engagement and impact, as well as cultivating new leaders for the organization and the field of toxicology.

Raegan B. O’Lone BA, MA, PhDMolecular Biology Specialty Section

Employer: HESI


Schools Attended: Boston University, PhD, Molecular Biology, Cell Biology, and Biochemistry, 2007; Boston University, MA, Molecular Biology, Cell Biology, and Biochemistry, 2005; Drew University, BA, Biology, BA German, 1999.

36


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Mid-Atlantic Regional Chapter 2007–present, Secretary/Treasurer 2001–2003, Councilor 2009–2012; Clinical and Translational Toxicology Specialty Section 2012–present; Comparative and Veterinary Specialty Section 2013–present, Secretary/Treasurer 2013–present; Drug Discovery Toxicology Specialty Section 2008–present; Medical Device and Combination Product Specialty Section 2012–present; Regulatory and Safety Evaluation Specialty Section 2012–present; Risk Assessment Specialty Section 2014–present; Toxicologic and Exploratory Pathology Specialty Section 2012–2013.

Experience: Dr. Mitchell has been involved in clinical and nonclinical safety evaluation and regulatory affairs for over 40 years. Currently, he is a regulatory and toxicology consultant to pharmaceutical, medical device and OTC companies. Previously, he worked in an academic toxicology laboratory (UCONN Health Center, labs of F. William Sunderman, Jr.) as well as for consumer products, pharmaceutical and consulting firms, Contract Research Organizations (CROs) and as a clinical toxicologist in hospitals. He is a senior adjunct lecturer at New York Medical College and New York University Medical School. Dr. Mitchell has a BA (Cell and Molecular Biology, UCONN), a MS (Medical Pharmacology, N Y Medical College) and a PhD (Toxicology, Joint Toxicology Program, UMDNJ-Rutgers University). Finally, he has been an active participant in various scientific organizations, including SOT, Mid-Atlantic Society of Toxicology (MASOT) and AACR for more than 30 years and previously has been a Secretary/Treasurer and a Councilor of MASOT.

Goals for SOT: To improve the organization by remaining scientifically current and forward looking to projected trends of toxicology.

John M. Mitchell MS, PhDComparative and Veterinary Specialty Section

Employer: NSF Health Sciences


Schools Attended: University of Medicine and Dentistry NJ/Rutgers University Joint Graduate Program, PhD, Toxicology/Pharmacology; New York Medical College, MS, Pharmacology; St. Joseph’s College, University of Hartford, Graduate Courses, Chemistry and Biology; University of Connecticut, BA, Biology and Physiological Psychology.

37



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Clinician-Scientist Engagement Task Force 2015–present; Committee on K–12 Education, Chair 2005–2006; Education Subcommittee for K–12 Education 2003–2005; Scientific Liaison Coalition 2010–present; Scientific Liaison Coalition—American Academy of Clinical Toxicology (AACT) 2013–present; SOT Liaison Coalition Representatives, (IUTOX) Councilor 2013–present; South Central Regional Chapter 2002–present, Vice President-Elect 2002–2003, Vice President 2003–2004, President 2004–2005, Past President 2005–2006, Regional Chapter Meeting Organizing Committee 2003 and 2009, Judge for the Graduate Student Awards, 2000, 2003, 2005, and 2008, Judge for Postdoctoral Awards 2015; Clinical and Translational Toxicology 2011–present, Interim Vice President 2011–2013, Vice President 2013–2014, President 2014–2015, Past President and Councilor 2015–present; Mechanisms Specialty Section 1984–present, Judge of the Carl Smith Graduate Student Awards 1989 and 2009; Specialty Section Collaboration and Communication Group 2013–2015, Co-Chair 2013–2014, Chair 2014–2015; Translational Impact Award 2010.

Experience: Dr. McMartin has worked in the Department of Pharmacology, Toxicology & Neuroscience at LSU Health Sciences Center, Shreveport from 1980–present as Professor and Director of Interdisciplinary Toxicology Program. His research focuses on mechanisms of renal toxicity. He also was recognized as a Postdoctoral Fellow for the Karolinska Institute in Stockholm from 1977–1979. Dr. McMartin has received the Kenneth Morgareidge Award in Toxicology from ILSI in 1988. In 2009 he was also recognized as a Fellow for the American Academy Clinical Toxicology. Dr. McMartin is currently on the Board of Scientific Counselors of the National Toxicology Program 2016–2019 and on the senior editorial board of Clinical Toxicology 2012–present. He is on the Board of Trustees of AACT 2010–present and a member of special emphasis panels on the NIH study section as well as reviewing reports by EPA and ATSDR. In addition, he serves on CERHR, WHO (IPCS), and NTP Expert Panels.

Goals for SOT: The Nominating Committee plays a critical role in helping SOT reach strategic goals. By serving on this committee, I would hope to help the Society choose its future leaders by finding suitable candidates for various positions. These persons will ultimately direct all of the Societies’ goals and accomplishments in the near future.

Kenneth E. McMartin PhDClinical and Translational Toxicology Specialty Section

Employer: Louisiana State University Health Sciences Center-Shreveport


Schools Attended: University of Iowa, PhD, Pharmacology, 1977; Coe College, BA, Chemistry, 1973.

38


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: North Carolina Regional Chapter 2002–present; Dermal Toxicology Specialty Section 2013–2014; Drug Discovery Toxicology Specialty Section 2003–present, Councilor 2009–2011, Vice President-Elect 2013–2014, Vice President 2014–2015, President 2015–present; In Vitro Specialty Section 2003–2014, Vice President 2006–2007, President 2007–2008, Past President 2008–2009; Mechanisms Specialty Section 2003–2004; Molecular and Systems Biology Specialty Section 2014–present; Neurotoxicology Specialty Section 2004–2009; Regulatory and Safety Evaluation Specialty Section 2003–2014; Toxicologic and Exploratory Pathology Specialty Section 2010–present, Councilor 2015–present.

Experience: Dr. Kemp currently serves as Director of Preclinical Toxicology Services and as a Hamner Associate Investigator at the Hamner Institutes for Health Sciences a position that he has held since June 2015. His previous positions have included: Senior Director Quality & Risk Management, Toxicology External Study Manager, Senior Toxicologist at GlaxoSmithKline from 2006–2015; and Preclinical Safety Scientist at Targacept from 2004–2006. Dr. Kemp has more than 11 years of experience designing and reporting regulated safety studies in a variety of species. He has represented molecules for the following indications diabetes, obesity, cognition, HIV, HCV, and smoking cessation. His background includes work with sandwich-cultured hepatocytes, hepatic transport, pharmacokinetic modeling, and leading a gastrointestinal and dermal safety training program. Dr. Kemp has received numerous awards while at GlaxoSmithKline (GSK) for his work in gastrointestinal safety and injury, third party oversight, dermal safety, and assistance with regulatory inspections. He received his DABT in 2012. He currently serves as a board member for the Professional Science Masters Program in Toxicology at the University of North Carolina.

Goals for SOT: If I am fortunate enough to be elected to the Nominating Committee, I will use all the resources available to recruit and develop candidates with strong leadership capabilities. I feel it is important to continually search for candidates that share SOT’s vision and goals, while maintaining a strong commitment to science and representing the diversity of SOT.

Daniel C. Kemp PhD, DABTDrug Discovery Toxicology Specialty Section

Employer: The Hamner Institutes for Health Sciences


Schools Attended: University of North Carolina, PhD, Toxicology, 2004; Michigan State University, BS, Biochemistry, 1999.

39



Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Ohio Valley Regional Chapter 2002–present; Biological Modeling Specialty Section 1996–present, Councilor 2005–2007, Vice President-Elect 2015–present; Inhalation and Respiratory Specialty Section 1996–present, Councilor 1999–2000.

Experience: Dr. Gearhart began his career working for Dr. R. O. McClellan at the Lovelace Inhalation Toxicology Research Institute (ITRI). With a Bachelor’s Degree in Biology, his research focused on determining the distribution of inhaled PuO2 particles in lung tissue and it’s redistribution through out the body. While working at ITRI, he returned to the University of New Mexico and worked on a Master’s Degree in Biology, with the primary focus on physiology and radiation biology, with Dr. McClellan as his major professor studying the distribution of PuO2 particles trapped in the liver after transfer from the lung. After completing his PhD at NYU (Dr. Schlesinger, Dr. Lippman) he focused on the chronic effects of environmental pollutants (Ozone, NOx, H2SO4) on respiratory tract defenses and the development of chronic lung disease, he took a staff scientist position at Wright Patterson AFB, working with Dr. Melvin Anderson and Dr. Harvey Clewell, learning the development and application of Physiologically Based Pharmacokinetic models in the human health risk of chemicals and materials in the USAF occupational setting. Dr. Gearhart left WPAFB in 1993 to work in the field of Human Health Risk Assessment with Dr. Kenny Crump and Dr. Clewell. In 1998–2000, he took the position of Inhalation Toxicologist with the Procter and Gamble Co., focused on providing safe personal care products. In 2000 Dr. Gearhart returned to WPAFB working for the USAF studying chemical and biological warfare agents, developing neurotherapeutics to combat nerve agent exposure. He currently is focused on providing safe exposure standards for USAF pilots of 4th generation fighter aircraft, as well as various other DoD occupational exposure settings.

Goals for SOT: My primary goals for SOT are to number one, to effectively publish, discuss and broadcast, the Society’s immense place in providing the public accurate information regarding the health risks of chemicals that are part of the myriad commercial and agricultural products at the interface of humans and their environment. Secondly, I strongly support the encouragement of the next generation of young developing toxicologists in training and those just beginning their careers. Lastly, it is most critical that members of the SOT take an active part in helping to shape not just the public understanding and opinion of the basic science that underpins the field of toxicology, but also that we as a society help to shape governmental guidelines on local, state and the federal level, to ensure the balance between creating the safest environment for all concerned, in conjunction with the economic welfare of the modern product market place.

Jeffery M. Gearhart PhD, DABTBiological Modeling Specialty Section

Employer: The Henry M. Jackson Foundation for Military Medicine


Schools Attended: New York University, PhD, Environmental Health/Toxicology. 1987; University of New Mexico, MS, Biology/Radiation Biology, 1980; University of New Mexico, BS, Biology, 1975.

40


Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards:: North Carolina Regional Chapter 2011–present; Biotechnology Specialty Section 2010–present; Immunotoxicology Specialty Section 1987–present, Vice President-Elect 2011–2012, Vice President 2012–2013, President 2013–2014, Past President 2014–2015; Specialty Section Collaboration and Communication Group 2013–2015.

Experience: Dr. Burleson received his PhD from the Medical College of Wisconsin with postdoctoral training at the University of Notre Dame. Broad areas of expertise include: immunotoxicology, clinical immunology, clinical microbiology, infectious diseases, immunomodulation, inflammation, immunopharmacology, cytokines, and pharmacogenomics. His background includes clinical experience at Milwaukee County General Hospital, academic associations at the University of Notre Dame and North Carolina State University, government regulatory immunotoxicology experience at the US EPA, and pharmaceutical experience in drug discovery at Procter & Gamble where his job responsibilities included head of core computer modeling to develop and validate a computer model of infectious disease with emphasis on inflammatory aspects of viral infection. He is co-founder, President and CEO of Burleson Research Technologies, Inc. (BRT), a CRO specializing in immunotoxicology since 1996 providing research laboratory services for pharmaceutical and biotech companies as well as the National Toxicology Program. His job responsibilities include development of strategy and business plans; setting operating objectives and goals for the life sciences; identifying new markets and analyzing potential markets for expansion. He is Senior Editor of Methods in Immunotoxicology, Volumes 1 and 2; a member of the editorial board of the Journal of Immunotoxicology and International Journal of Toxicology; Scientific Consultant, Science Review Board, US EPA; and is Past President of the Immunotoxicology Discussion Group (IDG) and the SOT Immunotoxicology Specialty Section. He served as Conference Chair, Immunotoxicology V Meeting; Organizer, Continuing Education Course titled “Immunotoxicology,” for 19th Annual Society of Toxicologic Pathology Meeting. He serves several times a year for NIH-NIAID Grant and Contract Reviews.

Goals for SOT: If elected, my goals for the SOT Nominating Committee would include identifying individuals with diverse backgrounds who are willing to serve in the elected positions of President-Elect, Secretary-Elect, Treasurer-Elect, Councilor, and representation on the Awards, Membership, and Nominating Committees. The Nominating Committee is crucial in selecting individuals who have strong leadership and communication skills, who will lead the Society in future areas to identify new technologies, promote international cooperation with toxicologists in other countries, support universities educating our next generation of toxicologists with mentoring programs, and identify increased avenues of support and education for training.

Memberships, Chairs, and/or Offices held in SOT Committees, Regional Chapters, Special Interest Groups, Specialty Sections, formerly or currently, and SOT Awards: Animals in Research Committee 1997–2000; Northern California Regional Chapter 1992–present, Founding Member, Councilor 1992–1993, Secretary 1995–1999, Councilor 2002–2003, Vice President 2003–2004, President-Elect 2004–2005, President 2005–2006, Past President 2006–2007; Hispanic Organization of Toxicologists Special Interest Group 2006–present, Vice President-Elect 2012–2013, Vice President 2013–2014, President 2014–2015, Past President 2015–present; Special Interest Group Collaboration and Communication Group 2013–2015; Carcinogenesis Specialty Section 1984–2011; Dermal Toxicology Specialty Section 1984–present; Drug Discovery Toxicology Specialty Section 1984–2005; Ocular Toxicology Specialty Section 2011–2014, Councilor 2012–2014; Regulatory and Safety Evaluation Specialty Section 1984–present, Councilor 2001–2003, Secretary/Treasurer 2003–2004; International ToxScholar grant recipient 2011.

Experience: Dr. DePass is Executive Director of Nonclinical Safety at Durect Corporation, Cupertino, California. He was Department Head, Toxicology at Roche Palo Alto (formerly Syntex and Roche Bioscience) and held various other positions at Roche and Syntex where he started working in June 1984. Before joining Syntex, he worked at Union Carbide Bushy Run Research Center where he was manager of oral and dermal toxicology. He is a member of the American College of Toxicology and AAAS. He was a member of the editorial board of Fundamental and Applied Toxicology from 1989 to 1995, and is a Diplomate of the American Board of Toxicology, and a Fellow of the Academy of Toxicological Sciences.

Goals for SOT: SOT is the largest toxicology organization in the world. I would like to see SOT continue to expand its efforts in global outreach with special emphasis on third world countries in the western hemisphere. In these countries, the opportunities for education and research in toxicology are much more limited than those in the USA. SOT has already established programs such as the Global Senior Scholar Exchange Program and the International ToxScholar Outreach Grant that have provided opportunities for US-based toxicologists to visit universities in third world countries and for senior scientists in other countries to spend time in US universities. As an adjunct to these programs, I would like to see SOT provide grants for graduate students and/or postdoctoral scholars from other western countries to attend the SOT meeting. I would propose one grant for the Caribbean region and Central America and a second grant for South America. These students would present their research at the meeting, network with other students and professionals, and then return to their home countries as ambassadors of SOT.

Gary R. Burleson PhDImmunotoxicology Specialty Section

Employer: Burleson Research Technologies, Inc. (BRT)


Schools Attended: Graduate work at the Medical College of Wisconsin and Postdoctoral work at the University of Notre Dame.

Linval R. DePass PhD, DABT, ATSDermal Toxicology Specialty Section

Employer: Durect Corporation


Schools Attended: University of Arkansas for Medical Sciences, PhD, 1978; University of Miami, MS, 1973; Georgetown University, BS, 1968.

Documents

Society of ToxicologyMcKeeman, Kim Boekelheide, Hanan N. Ghantous, Angela J. Harris, Michael P. Holsapple, B. Paige Lawrence, Jean F. Regal, Lynette K. Rogers, Sharmilee P. Sawant,